<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mar Drugs</journal-id><journal-id journal-id-type="iso-abbrev">Mar Drugs</journal-id><journal-id journal-id-type="publisher-id">marinedrugs</journal-id><journal-title-group><journal-title>Marine Drugs</journal-title></journal-title-group><issn pub-type="epub">1660-3397</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6835697</article-id><article-id pub-id-type="doi">10.3390/md17100567</article-id><article-id pub-id-type="publisher-id">marinedrugs-17-00567</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Griffithsin, a Highly Potent Broad-Spectrum Antiviral Lectin from Red Algae: From Discovery to Clinical Application</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4630-8428</contrib-id><name><surname>Lee</surname><given-names>Choongho</given-names></name></contrib></contrib-group><aff id="af1-marinedrugs-17-00567">College of Pharmacy, Dongguk University, Goyang 10326, Korea; <email>lkj640@gmail.com</email>; Tel.: +82-31-961-5223</aff><pub-date pub-type="epub"><day>06</day><month>10</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2019</year></pub-date><volume>17</volume><issue>10</issue><elocation-id>567</elocation-id><history><date date-type="received"><day>16</day><month>9</month><year>2019</year></date><date date-type="accepted"><day>03</day><month>10</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 by the author.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Virus entry into a susceptible host cell is the first step in the formation of all viral diseases. Controlling viral infections by disrupting viral entry is advantageous for antibody-mediated neutralization by the host&#x02019;s immune system and as a preventive and therapeutic antiviral strategy. Recently, several plant-derived carbohydrate-binding proteins (lectins) have emerged as a new class of antiviral biologics by taking advantage of a unique glycosylation pattern only found on the surface of viruses. In particular, a red algae-derived griffithsin (GRFT) protein has demonstrated superior in vitro and in vivo antiviral activity with minimum host toxicity against a variety of clinically relevant, enveloped viruses. This review examines the structural characteristics of GRFT, focusing on its carbohydrate-binding capability. Its in vitro antiviral profiles against human immunodeficiency virus (HIV) are also discussed followed by a description of the results from a combination study using anti-HIV drugs. The results of several studies regarding its novel antiviral mechanism of action are provided in conjunction with an explanation of viral resistance profiles to GRFT. In addition, its in vitro and in vivo host toxicity profiles are summarized with its pharmacokinetic behavior using in vivo efficacy study results. Also, a large-scale production and formulation strategy, as well as a drug delivery strategy, for GRFT as a new class of broad-spectrum microbicides is discussed. Finally, results from two ongoing clinical studies examining GRFT&#x02019;s effects on viruses are presented.</p></abstract><kwd-group><kwd>griffithsin (GRFT)</kwd><kwd>lectin</kwd><kwd>carbohydrate-binding</kwd><kwd>human immunodeficiency virus (HIV)</kwd><kwd>microbicide</kwd><kwd>virus entry inhibitor</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-marinedrugs-17-00567"><title>1. Introduction</title><p>Every virus starts its life cycle by entering a susceptible host cell. The host cell-targeting ability of a virus is mainly determined by the presence of appropriate host cell receptors which are engaged by a virus. For successful host cell entry, enveloped viruses have evolved a diverse array of envelope glycoproteins on their membrane with different receptor association capabilities. The best-characterized example of this viral glycoprotein&#x02013;host cell receptor relationship might be the interaction between the human immunodeficiency virus (HIV) glycoprotein gp120 and the human T lymphocyte CD4 molecule. Due to its essential role in the overall virus life cycle, viral entry has been an attractive target for both vaccine and antiviral drug development with the goal of disrupting the binding of viral glycoproteins to host cell receptors. In addition, heavy and unique glycosylation patterns found only on viral glycoproteins provide another level of virus specificity, which could increase the selectivity of virus-targeting therapeutics and prophylactics. In this regard, the use of carbohydrate-binding proteins, collectively called &#x0201c;lectins&#x0201d;, has been explored as a new therapeutic antiviral strategy. Recently discovered virus-targeting lectins include banana lectin [<xref rid="B1-marinedrugs-17-00567" ref-type="bibr">1</xref>], cyanovirin [<xref rid="B2-marinedrugs-17-00567" ref-type="bibr">2</xref>], microvirin [<xref rid="B3-marinedrugs-17-00567" ref-type="bibr">3</xref>], scytovirin [<xref rid="B4-marinedrugs-17-00567" ref-type="bibr">4</xref>], and griffithsin (GRFT) [<xref rid="B5-marinedrugs-17-00567" ref-type="bibr">5</xref>]. Among them, GRFT has been studied extensively for the development of either antiviral therapeutics or preventive microbicides due to its extreme potency, low in vitro and in vivo host toxicity, and favorable subclinical outcomes. </p><p>Serious endeavors to develop antiviral therapeutics and vaccines against HIV began during the epidemics of the early 1980s. HIV infection was linked with the development of acquired immune deficiency syndrome (AIDS). With no effective antiviral drugs available during that time, a diagnosis of HIV infection was a death sentence for most patients [<xref rid="B6-marinedrugs-17-00567" ref-type="bibr">6</xref>]. However, the introduction of highly active antiretroviral therapy (HAART) improved patient outcomes, rendering AIDS as a clinically manageable disease. However, a lack of preventive measures such as an HIV vaccine has hindered efforts to decrease the number of new HIV cases per year. Particularly, young women who live in resource-poor and HIV-endemic regions such as sub-Saharan Africa [<xref rid="B7-marinedrugs-17-00567" ref-type="bibr">7</xref>] have been the most vulnerable population to new HIV infections since they do not have the freedom to control sexual situations or use protective devices. Individuals who practice unprotected receptive anal intercourse (URAI) are also responsible for the ongoing spread of new HIV infections because of a high preponderance of HIV target cells in the traumatized rectal mucosal area [<xref rid="B8-marinedrugs-17-00567" ref-type="bibr">8</xref>]. Therefore, these two HIV-vulnerable populations need new types of HIV prevention strategies. To that end, topical anti-HIV microbicides such as creams, gels, or intravaginal rings could be promising, with on-demand pre-exposure prophylactic options not only for vulnerable populations but also for the general public. </p><p>GRFT is a red algae-derived lectin of 121 amino acids (<xref ref-type="fig" rid="marinedrugs-17-00567-f001">Figure 1</xref>). It exhibits potent (EC<sub>50</sub> in the picomolar range) and broad-spectrum antiviral activity and negligible in vitro and in vivo host toxicity [<xref rid="B9-marinedrugs-17-00567" ref-type="bibr">9</xref>]. Its antiviral activity relates to a unique structural feature that forms a homodimeric complex with three carbohydrate-binding domains on each monomer (<xref ref-type="fig" rid="marinedrugs-17-00567-f002">Figure 2</xref>). These three carbohydrate-binding domains target high-mannose arrays present on many pathogenic enveloped viruses including HIV; severe, acute, or Middle East respiratory syndrome coronaviruses (SARS-CoV or MERS-CoV) [<xref rid="B10-marinedrugs-17-00567" ref-type="bibr">10</xref>,<xref rid="B11-marinedrugs-17-00567" ref-type="bibr">11</xref>]; hepatitis C virus (HCV) [<xref rid="B12-marinedrugs-17-00567" ref-type="bibr">12</xref>,<xref rid="B13-marinedrugs-17-00567" ref-type="bibr">13</xref>]; herpes simplex virus 2 (HSV-2) [<xref rid="B14-marinedrugs-17-00567" ref-type="bibr">14</xref>,<xref rid="B15-marinedrugs-17-00567" ref-type="bibr">15</xref>]; Japanese encephalitis virus (JEV) [<xref rid="B16-marinedrugs-17-00567" ref-type="bibr">16</xref>,<xref rid="B17-marinedrugs-17-00567" ref-type="bibr">17</xref>]; and porcine epidemic diarrhea virus (PEDV) [<xref rid="B18-marinedrugs-17-00567" ref-type="bibr">18</xref>]. As a result of its broad antiviral spectrum, it shows great promise as a general microbicidal agent that can prevent viral transmission and as a therapeutic against enveloped virus-mediated diseases. From discovery to clinical development, much interest has surrounded GRFT because of its potential to be the first clinically proven, preventive measure against various viral diseases. In this review, the structural characteristics of GRFT are examined. Also, its in vitro antiviral activity against HIV, which is the most studied target pathogen for GRFT so far, is discussed in detail using a variety of combination study results involving current antiretroviral drugs. The antiviral mechanism of action for GRFT is explained in conjunction with viral resistance profiles to GRFT. In addition, its in vitro and in vivo toxicity profiles are summarized, and its pharmacokinetic and in vivo efficacy study results are delineated. To provide a practical drug development perspective, a large-scale production and formulation strategy as well as a drug delivery strategy for GRFT as an HIV-preventive biologic is discussed. Finally, ongoing clinical studies of GRFT and its effects on viruses other than HIV are summarized. </p></sec><sec id="sec2-marinedrugs-17-00567"><title>2. Structure</title><p>GRFT is a carbohydrate-binding protein made of 121 amino acids and is 12.7 kDa in size [<xref rid="B9-marinedrugs-17-00567" ref-type="bibr">9</xref>]. It has a unique amino acid residue at position 31 which does not match any of the 20 standard amino acids [<xref rid="B5-marinedrugs-17-00567" ref-type="bibr">5</xref>] (<xref ref-type="fig" rid="marinedrugs-17-00567-f001">Figure 1</xref>). It was initially isolated from an aqueous extract of the red algae <italic>Griffithsia</italic> sp. collected from waters off the shores of New Zealand. Researchers at the U.S. National Cancer Institute first reported its potent cytoprotective activity against HIV-1 in T-lymphoblastoid cells [<xref rid="B5-marinedrugs-17-00567" ref-type="bibr">5</xref>]. Five research papers reported structural results on GRFT by using either X-ray crystallography or nuclear magnetic resonance (NMR) techniques (<xref rid="marinedrugs-17-00567-t001" ref-type="table">Table 1</xref>) [<xref rid="B19-marinedrugs-17-00567" ref-type="bibr">19</xref>,<xref rid="B20-marinedrugs-17-00567" ref-type="bibr">20</xref>,<xref rid="B21-marinedrugs-17-00567" ref-type="bibr">21</xref>,<xref rid="B22-marinedrugs-17-00567" ref-type="bibr">22</xref>,<xref rid="B23-marinedrugs-17-00567" ref-type="bibr">23</xref>]. In terms of structural classification, GRFT is a Jacalin-related lectin harboring three repeats of an antiparallel four-stranded &#x003b2;-sheet with a triangular prism shape (<xref ref-type="fig" rid="marinedrugs-17-00567-f002">Figure 2</xref>) [<xref rid="B19-marinedrugs-17-00567" ref-type="bibr">19</xref>]. It is called a domain-swapped dimer because two &#x003b2;-strands from one protein forming the dimer display domain-exchanging properties with the same two &#x003b2;-strands of its counterpart [<xref rid="B19-marinedrugs-17-00567" ref-type="bibr">19</xref>]. It has three identical carbohydrate-binding sites (located within residues 20&#x02013;34, 58&#x02013;76, and 96&#x02013;120) on each monomer with three conserved glycine-rich repeats (GGSGG) [<xref rid="B19-marinedrugs-17-00567" ref-type="bibr">19</xref>]. It is estimated that as many as 11 high-mannose oligosaccharides are present on one HIV-1 gp120 protein. Therefore, GRFT&#x02019;s multivalent interactions with gp120 via these three carbohydrate-binding domains seem to be essential for its high-affinity and anti-HIV-1 potency at low concentrations (picomolar range) [<xref rid="B22-marinedrugs-17-00567" ref-type="bibr">22</xref>]. In particular, three aspartate residues in these carbohydrate-binding sites (Asp30, Asp70, and Asp112) play a critical role in the interaction of GRFT with high-mannose type oligosaccharides such as Man9GlcNAc2, which is composed of nine mannose molecules and two <italic>N</italic>-acetyl glucosamines [<xref rid="B22-marinedrugs-17-00567" ref-type="bibr">22</xref>]. This was supported by a study demonstrating that GRFT point mutations (D30A, D70A, or D112A) partially inhibit its ability to bind to gp120, and a GRFT mutant with all three mutations loses almost all of its binding capacity [<xref rid="B21-marinedrugs-17-00567" ref-type="bibr">21</xref>]. In addition, tyrosine residues such as Tyr28, Tyr68, and Tyr110 are necessary for GRFT to bind to carbohydrates [<xref rid="B24-marinedrugs-17-00567" ref-type="bibr">24</xref>]. However, the apparent disparity between the gp120-binding ability and HIV-1 inhibitory potency for these GRFT variants indicates the existence of another antiviral mechanism beyond simple gp120-GRFT binding [<xref rid="B21-marinedrugs-17-00567" ref-type="bibr">21</xref>]. With regard to carbohydrate-binding specificity, all six GRFT dimer carbohydrate-binding sites can be occupied by mannose, glucose, <italic>N</italic>-acetyl glucosamine, and 1-6 &#x003b1;-mannobiose with similar affinities [<xref rid="B23-marinedrugs-17-00567" ref-type="bibr">23</xref>]. To determine whether GRFT must form a dimer to exert its antiviral activity, a monomeric form of GRFT (mGRFT) was created by inserting either two or four amino acids at its dimerization interface. mGRFT possesses greatly reduced antiviral activity against HIV-1 in spite of its comparable association with high-mannose oligosaccharides, since mGRFT possesses all three carbohydrate-binding sites [<xref rid="B20-marinedrugs-17-00567" ref-type="bibr">20</xref>]. This suggests that the intact dimeric form of GRFT is required to efficiently disrupt HIV-1 infectivity [<xref rid="B20-marinedrugs-17-00567" ref-type="bibr">20</xref>].</p></sec><sec id="sec3-marinedrugs-17-00567"><title>3. Anti-HIV-1 Activity and Cytotoxicity in Vitro</title><p>Several studies have described the in vitro anti-HIV activities and cytotoxicity of GRFT (<xref rid="marinedrugs-17-00567-t002" ref-type="table">Table 2</xref>) [<xref rid="B5-marinedrugs-17-00567" ref-type="bibr">5</xref>,<xref rid="B25-marinedrugs-17-00567" ref-type="bibr">25</xref>,<xref rid="B26-marinedrugs-17-00567" ref-type="bibr">26</xref>,<xref rid="B27-marinedrugs-17-00567" ref-type="bibr">27</xref>,<xref rid="B28-marinedrugs-17-00567" ref-type="bibr">28</xref>,<xref rid="B29-marinedrugs-17-00567" ref-type="bibr">29</xref>,<xref rid="B30-marinedrugs-17-00567" ref-type="bibr">30</xref>,<xref rid="B31-marinedrugs-17-00567" ref-type="bibr">31</xref>,<xref rid="B32-marinedrugs-17-00567" ref-type="bibr">32</xref>]. Mori et al. reported potent, sub-nanomolar antiviral efficacy of both native and recombinant GRFT against laboratory strains and primary isolates of T- and M- tropic HIV-1 [<xref rid="B5-marinedrugs-17-00567" ref-type="bibr">5</xref>]. In their publication, they observed that GRFT inhibited soluble gp120 from binding to CD4 receptor-expressing cells [<xref rid="B5-marinedrugs-17-00567" ref-type="bibr">5</xref>]. Cell-to-cell fusion and transmission of HIV-1 infection were also blocked by GRFT at similar concentrations [<xref rid="B5-marinedrugs-17-00567" ref-type="bibr">5</xref>]. In addition, the coadministration of monosaccharides such as glucose, mannose, and <italic>N</italic>-acetyl glucosamine hindered glycosylation-dependent binding of GRFT to soluble gp120 [<xref rid="B5-marinedrugs-17-00567" ref-type="bibr">5</xref>]. In parallel with this observation, Emau et al. also demonstrated that GRFT could block the infectivity of CXCR4- and CCR5-tropic HIV viruses at picomolar concentrations. They also confirmed the long-term stability of GRFT in a cervical/vaginal lavage [<xref rid="B27-marinedrugs-17-00567" ref-type="bibr">27</xref>]. In order to harness the HIV-inactivating power of GRFT, a new peptide called grifonin-1 was designed based on the three carbohydrate-binding amino acid sequences of GRFT. Its sub-micromolar anti-HIV activity was confirmed using an in vitro TZM-bl cell line and p24 gag antigen release assays [<xref rid="B24-marinedrugs-17-00567" ref-type="bibr">24</xref>]. In addition to its ability to suppress HIV-1 transmission in CD4+ T-lymphocytes, GRFT also subverted DC-SIGN (dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin)-mediated HIV capture [<xref rid="B30-marinedrugs-17-00567" ref-type="bibr">30</xref>]. Mechanistically, a binding competition between GRFT and gp120 for DC-SIGN was proposed as a potential mode of action for GRFT-mediated inhibition of HIV-1 capture by DC-SIGN [<xref rid="B21-marinedrugs-17-00567" ref-type="bibr">21</xref>]. Corresponding to this DC-SIGN-dependent antiviral activity, GRFT also potently inhibited giant cell formation between persistently HIV-infected T cells and noninfected CD4+ target T cells. This led to the suppression of HIV transmission, CD4+ T-cell destruction, and ultimately viral replication through the DC-SIGN mediated pathway [<xref rid="B33-marinedrugs-17-00567" ref-type="bibr">33</xref>]. This efficient blockage of the binding of DC-SIGN to immobilized gp120 by GRFT was further confirmed [<xref rid="B21-marinedrugs-17-00567" ref-type="bibr">21</xref>]. This observation was in harmony with the GRFT-mediated expulsion of gp120 from the gp120/DC-SIGN complex [<xref rid="B21-marinedrugs-17-00567" ref-type="bibr">21</xref>]. Interestingly, this highly potent inhibition of DC-SIGN-mediated capture and transmission by GRFT was markedly impaired when GRFT was mutated in one of its three carbohydrate-binding sites (D30A, D70A, or D112A) [<xref rid="B21-marinedrugs-17-00567" ref-type="bibr">21</xref>], further implicating its carbohydrate-binding sites as critical determinants for anti-HIV-1 activity. Regarding its cytotoxicity, two studies demonstrated that the CC<sub>50</sub> concentration for GRFT was several hundred nanomolar [<xref rid="B5-marinedrugs-17-00567" ref-type="bibr">5</xref>,<xref rid="B27-marinedrugs-17-00567" ref-type="bibr">27</xref>], thousands of times higher than its reported antiviral concentrations.</p></sec><sec id="sec4-marinedrugs-17-00567"><title>4. Drug Combination</title><p>Four studies have described the combination effects of GRFT with either current anti-HIV drugs or potential therapeutics under development (<xref rid="marinedrugs-17-00567-t003" ref-type="table">Table 3</xref>) [<xref rid="B26-marinedrugs-17-00567" ref-type="bibr">26</xref>,<xref rid="B28-marinedrugs-17-00567" ref-type="bibr">28</xref>,<xref rid="B29-marinedrugs-17-00567" ref-type="bibr">29</xref>,<xref rid="B32-marinedrugs-17-00567" ref-type="bibr">32</xref>]. GRFT showed synergistic antiviral activity with tenofovir, maraviroc (a CCR5 antagonist), and enfuvirtide (a gp41 fusion peptide inhibitor) [<xref rid="B29-marinedrugs-17-00567" ref-type="bibr">29</xref>]. The different glycosylation patterns on the viral envelope of clade B and clade C gp120 had no observable effect on their synergistic antiviral action [<xref rid="B29-marinedrugs-17-00567" ref-type="bibr">29</xref>]. Covalently linking GRFT to the gp41-binding peptide C37 also exhibited a potency several-fold greater than that of GRFT alone in inhibiting HIV Env-mediated fusion in a CCR5-tropic cell-cell fusion assay [<xref rid="B32-marinedrugs-17-00567" ref-type="bibr">32</xref>]. In line with this observation, all GRFT/antiretroviral drug (entry inhibitors, reverse transcriptase inhibitors, integrase inhibitors, and protease inhibitors) combinations displayed either synergistic or additive effects in inhibiting cell&#x02013;cell fusion and protected against target CD4+ T cell destruction [<xref rid="B33-marinedrugs-17-00567" ref-type="bibr">33</xref>]. GRFT/antiretroviral combinations also potently inhibited short-term viral replication in T-cells via DC-SIGN-mediated transmission [<xref rid="B33-marinedrugs-17-00567" ref-type="bibr">33</xref>]. Combinations of GRFT and other carbohydrate-binding agents (CBAs) including <italic>Hippeastrum</italic> hybrid agglutinin, <italic>Galanthus nivalis</italic> agglutinin, a mannose-specific monoclonal antibody (mAb) (2G12), microvirin, and banana lectin also showed synergistic activity against HIV-1, HIV-2, and even against certain CBA-resistant HIV-1 strains [<xref rid="B28-marinedrugs-17-00567" ref-type="bibr">28</xref>]. None of the CBAs competed with each other&#x02019;s glycan-binding sites on gp120 since they have distinct binding patterns on the gp120 envelope [<xref rid="B28-marinedrugs-17-00567" ref-type="bibr">28</xref>]. In addition to antiviral synergy, gp120-GRFT complexes showed higher immunogenicity than the individual proteins per se. This suggests that removing the mannose moieties on monomeric gp120 improves the humoral immune response to this protein [<xref rid="B34-marinedrugs-17-00567" ref-type="bibr">34</xref>].</p></sec><sec id="sec5-marinedrugs-17-00567"><title>5. Anti-HIV-1 Mechanism of Action </title><p>Six different antiviral mechanisms of action against HIV-1 by GRFT have been proposed (<xref rid="marinedrugs-17-00567-t004" ref-type="table">Table 4</xref>) [<xref rid="B26-marinedrugs-17-00567" ref-type="bibr">26</xref>,<xref rid="B30-marinedrugs-17-00567" ref-type="bibr">30</xref>,<xref rid="B34-marinedrugs-17-00567" ref-type="bibr">34</xref>,<xref rid="B35-marinedrugs-17-00567" ref-type="bibr">35</xref>,<xref rid="B36-marinedrugs-17-00567" ref-type="bibr">36</xref>,<xref rid="B37-marinedrugs-17-00567" ref-type="bibr">37</xref>]. A carbohydrate binding-dependent antiviral mechanism of GRFT was explored by using HIV-specific neutralizing monoclonal antibodies (mAbs) such as 2G12, 48d, b12, and b6 [<xref rid="B25-marinedrugs-17-00567" ref-type="bibr">25</xref>,<xref rid="B26-marinedrugs-17-00567" ref-type="bibr">26</xref>]. GRFT preferentially inhibited gp120 from binding to the 2G12 mAb, which targets N-linked glycans at positions 332, 339, and 392 on gp120. This suggests an overlapping binding specificity with the 2G12 mAb [<xref rid="B25-marinedrugs-17-00567" ref-type="bibr">25</xref>]. In addition, GRFT increased the interaction between gp120 and the 48d mAb, which recognizes a CD4-induced epitope [<xref rid="B25-marinedrugs-17-00567" ref-type="bibr">25</xref>]. GRFT also enhanced the binding of HIV-1 to plates coated with b12 and b6 mAbs [<xref rid="B26-marinedrugs-17-00567" ref-type="bibr">26</xref>]. This indicates that the binding of GRFT to gp120 triggers the exposure of the CD4-binding site on gp120. In particular, the glycan at position 386, which shields the CD4 binding domain of gp120, is also involved in the GRFT-mediated binding enhancements and the neutralization synergy between GRFT and b12 [<xref rid="B26-marinedrugs-17-00567" ref-type="bibr">26</xref>]. In addition, a synergy between GRFT and b12 was also exhibited when HIV-1 isolates became more sensitive to neutralization upon increasing HIV-1 binding of GRFT to b12 and b6 mAbs [<xref rid="B26-marinedrugs-17-00567" ref-type="bibr">26</xref>]. Together, these data suggest that GRFT-mediated blockage of a post-CD4 receptor binding event, such as the coreceptor binding with gp120, might be another plausible mechanism through which GRFT inhibits HIV-1 infection [<xref rid="B26-marinedrugs-17-00567" ref-type="bibr">26</xref>]. Since the glycans on HIV-1 gp120 play an important role in shielding neutralization-sensitive epitopes from antibody recognition [<xref rid="B26-marinedrugs-17-00567" ref-type="bibr">26</xref>], disruption of the mannose molecules on gp120 by GRFT may also increase antibody-dependent neutralization of HIV-1 particles. </p><p>Although the multivalent interaction of GRFT with high-mannose oligosaccharides is believed to account for most of its picomolar antiviral potency, the looser correlation between gp120-binding ability and HIV inhibitory potency for the binding site mutants of GRFT suggests the possibility of another unknown antiviral mechanism of GRFT that is not based on simple gp120 binding [<xref rid="B21-marinedrugs-17-00567" ref-type="bibr">21</xref>]. According to an isothermal titration calorimetry binding study, GRFT bound to glucose and <italic>N</italic>-acetyl glucosamine in a similar fashion to that of mannose, demonstrating its flexible specificity in binding carbohydrates [<xref rid="B23-marinedrugs-17-00567" ref-type="bibr">23</xref>]. This binding flexibility might have an implication for its broad antiviral spectrum. To study the potential role of the GRFT dimer in the suppression of HIV-1 infectivity, either two or four amino acids were inserted at the dimerization interface of GRFT. This resulted in a monomeric form of GRFT (mGRFT) with greatly reduced antiviral activity against HIV-1. These results further emphasize the importance of multivalent interactions between dimeric GRFT and oligosaccharides present on HIV envelope glycoproteins for the successful cross-linking and aggregation of viral particles [<xref rid="B20-marinedrugs-17-00567" ref-type="bibr">20</xref>]. Interestingly, an obligate dimer of GRFT with a peptide linker between the two subunits altered the structure of gp120 by exposing the CD4 binding site. However, GRFT-linker-GRFT with mutated carbohydrate-binding sites largely lost this ability [<xref rid="B37-marinedrugs-17-00567" ref-type="bibr">37</xref>]. On the other hand, the glycan-specific DC-SIGN receptor binds the virus and mediates its transfer to CD4+ cells [<xref rid="B38-marinedrugs-17-00567" ref-type="bibr">38</xref>]. In this regard, GRFT&#x02019;s ability to partially block gp120 from binding to human DC-SIGN [<xref rid="B34-marinedrugs-17-00567" ref-type="bibr">34</xref>] and its potent inhibition of DC-SIGN-dependent transfer of HIV-1 [<xref rid="B38-marinedrugs-17-00567" ref-type="bibr">38</xref>] could synergize with its antiviral action by blocking viral entry. To maximize the antiviral synergy caused by GRFT multimerization, tandem repeats of mGRFT (mGRFT tandemers) were engineered. They displayed picomolar-level antiviral activity in whole-cell anti-HIV assays [<xref rid="B37-marinedrugs-17-00567" ref-type="bibr">37</xref>]. However, since mGRFT tandemers could not aggregate HIV virions, Moulaei et al. suggested the intra-virion crosslinking of HIV envelope glycoproteins may be more integral to their antiviral activity [<xref rid="B36-marinedrugs-17-00567" ref-type="bibr">36</xref>]. Inter-virion aggregation or clustering of HIV-1 gp120 on the viral membrane was found to be related to neutralization potency [<xref rid="B35-marinedrugs-17-00567" ref-type="bibr">35</xref>]. </p></sec><sec id="sec6-marinedrugs-17-00567"><title>6. Resistance</title><p>Five studies have characterized viral resistance profiles caused by chronic GRFT treatment (<xref rid="marinedrugs-17-00567-t005" ref-type="table">Table 5</xref>) [<xref rid="B25-marinedrugs-17-00567" ref-type="bibr">25</xref>,<xref rid="B26-marinedrugs-17-00567" ref-type="bibr">26</xref>,<xref rid="B31-marinedrugs-17-00567" ref-type="bibr">31</xref>,<xref rid="B39-marinedrugs-17-00567" ref-type="bibr">39</xref>,<xref rid="B40-marinedrugs-17-00567" ref-type="bibr">40</xref>]. Since the antiviral activity of GRFT mainly depends on disrupting the biological functions of multiple mannose molecules on viral glycoproteins, a reduction in the glycosylation levels of a target protein can lead to GRFT resistance. For example, the 234 and 295 glycosylation sites are involved in GRFT-induced HIV-1 neutralization since a concomitant lack of glycans at both positions resulted in natural GRFT resistance [<xref rid="B25-marinedrugs-17-00567" ref-type="bibr">25</xref>]. Conversely, introducing glycosylation sites at N234 and N295 in HIV-1 clade C virus increased GRFT antiviral potency [<xref rid="B25-marinedrugs-17-00567" ref-type="bibr">25</xref>]. In line with these observations, deglycosylation at position 295 or 448 decreased the sensitivity of a single transmitter/founder HIV Env to GRFT [<xref rid="B31-marinedrugs-17-00567" ref-type="bibr">31</xref>]. Since N295 and N448 are GRFT-specific, high-mannose, N-linked glycosylation sites on gp120, a single deglycosylation at N295 or N448 in primary or T-cell-line-adapted HIV-1 isolates also resulted in marked resistance to GRFT [<xref rid="B40-marinedrugs-17-00567" ref-type="bibr">40</xref>]. Furthermore, glycosylation sites at positions 230, 234, 241, and 289 located in the C2 region and 339, 392, and 448 in the C3&#x02013;C4 region were also implicated in GRFT resistance [<xref rid="B39-marinedrugs-17-00567" ref-type="bibr">39</xref>]. A loss of glycosylation sites on gp120 as well as a rearrangement of glycans in V4 also led to HIV-1 subtype C resistance against GRFT [<xref rid="B39-marinedrugs-17-00567" ref-type="bibr">39</xref>]. In the case of DC-SIGN-dependent antiviral activity of GRFT, the effects of extra glycosylation seem to be dependent on the location of the glycosylation. For example, the introduction of the 234 glycosylation site abolished HIV-1 sensitivity to lectin&#x02019;s ability to inhibit binding to DC-SIGN and virus transfer [<xref rid="B38-marinedrugs-17-00567" ref-type="bibr">38</xref>]. However, the addition of the 295 glycosylation site enhanced the inhibition of DC-SIGN-dependent HIV-1 transfer by GRFT [<xref rid="B38-marinedrugs-17-00567" ref-type="bibr">38</xref>]. Given the overlapping nature of the binding specificity displayed by GRFT and neutralizing antibodies against HIV-1, GRFT resistance could also affect HIV-1 sensitivity to antibody-dependent neutralization.</p></sec><sec id="sec7-marinedrugs-17-00567"><title>7. Toxicity</title><p>The ubiquitous nature of glycosylated proteins in the body raises concerns that GRFT may cause toxicity by interacting with glycosylated host proteins. For this reason, the effects of GRFT on host cells and animals have been studied extensively. According to five previous reports, GRFT does not exhibit any toxicity at its active antiviral concentrations (<xref rid="marinedrugs-17-00567-t006" ref-type="table">Table 6</xref>) [<xref rid="B28-marinedrugs-17-00567" ref-type="bibr">28</xref>,<xref rid="B41-marinedrugs-17-00567" ref-type="bibr">41</xref>,<xref rid="B42-marinedrugs-17-00567" ref-type="bibr">42</xref>,<xref rid="B43-marinedrugs-17-00567" ref-type="bibr">43</xref>,<xref rid="B44-marinedrugs-17-00567" ref-type="bibr">44</xref>,<xref rid="B45-marinedrugs-17-00567" ref-type="bibr">45</xref>]. GRFT induced only minimal changes in the secretion of inflammatory cytokines and chemokines by epithelial cells and human peripheral blood mononuclear cells (PBMCs) [<xref rid="B43-marinedrugs-17-00567" ref-type="bibr">43</xref>]. In addition, it had no measurable effect on cell viability or the levels of T-cell activation markers [<xref rid="B43-marinedrugs-17-00567" ref-type="bibr">43</xref>]. GRFT treatment induced only minimal alterations in the gene expression profile of human ectocervical cells [<xref rid="B43-marinedrugs-17-00567" ref-type="bibr">43</xref>]. It also caused no significant cell death, mitogenicity, activation, or cytokine release in mouse PBMCs [<xref rid="B44-marinedrugs-17-00567" ref-type="bibr">44</xref>]. No obvious changes were observed in animal fitness, blood chemistry, or complete blood count parameters in GRFT-treated mice [<xref rid="B44-marinedrugs-17-00567" ref-type="bibr">44</xref>]. Interestingly, the PBMC-bound form of GRFT was still able to maintain its antiviral activity, raising the potential of its versatile in vivo antiviral activity [<xref rid="B43-marinedrugs-17-00567" ref-type="bibr">43</xref>]. Chronic intravaginal or systemic administration of 2 mg/kg of GRFT was also non-toxic in mice [<xref rid="B44-marinedrugs-17-00567" ref-type="bibr">44</xref>]. GRFT, when administered in gel form, was not associated with any changes in the rectal proteome [<xref rid="B42-marinedrugs-17-00567" ref-type="bibr">42</xref>]. An increased abundance of two common and beneficial microbial taxa after GRFT treatment was due to placebo formulations and not to GRFT, itself [<xref rid="B42-marinedrugs-17-00567" ref-type="bibr">42</xref>]. This association between the placebo gel and changes in the rectal proteome and microbiota indicates the need to alter the components of the placebo gel in future studies [<xref rid="B42-marinedrugs-17-00567" ref-type="bibr">42</xref>]. GRFT was also well tolerated after subcutaneous administration in guinea pig and mouse models [<xref rid="B41-marinedrugs-17-00567" ref-type="bibr">41</xref>]. In addition, GRFT was found to be non-irritating and non-inflammatory in human cervical explants and in an in vivo rabbit vaginal irritation model [<xref rid="B45-marinedrugs-17-00567" ref-type="bibr">45</xref>]. In this study, no mitogenic activity was reported in cultured human lymphocytes treated with GRFT [<xref rid="B45-marinedrugs-17-00567" ref-type="bibr">45</xref>]. However, following GRFT treatment, reversible splenomegaly was observed with the activation of certain spleen B and T cells [<xref rid="B44-marinedrugs-17-00567" ref-type="bibr">44</xref>]. This GRFT-associated increase in spleen and liver mass was also noted in another study [<xref rid="B41-marinedrugs-17-00567" ref-type="bibr">41</xref>]. Therefore, an immune response elicited by GRFT treatment should be controlled in order to avoid potential GRFT immune-related toxicity [<xref rid="B41-marinedrugs-17-00567" ref-type="bibr">41</xref>].</p></sec><sec id="sec8-marinedrugs-17-00567"><title>8. Pharmacokinetic and in Vivo Efficacy Studies</title><p>Three studies were conducted to examine the in vivo antiviral efficacy and pharmacokinetic behavior of GRFT using various small animal models (<xref rid="marinedrugs-17-00567-t007" ref-type="table">Table 7</xref>) [<xref rid="B41-marinedrugs-17-00567" ref-type="bibr">41</xref>,<xref rid="B46-marinedrugs-17-00567" ref-type="bibr">46</xref>,<xref rid="B47-marinedrugs-17-00567" ref-type="bibr">47</xref>]. Subcutaneous injections of GRFT into guinea pigs and mice were very well tolerated, resulting in the accumulation of GRFT up to relevant therapeutic concentrations [<xref rid="B41-marinedrugs-17-00567" ref-type="bibr">41</xref>]. The serum from GRFT-treated animals was found to retain antiviral activity against HIV-1-enveloped pseudoviruses in a cell-based neutralization assay [<xref rid="B41-marinedrugs-17-00567" ref-type="bibr">41</xref>]. In addition, active GRFT, which is capable of neutralizing HIV-Env pseudoviruses, was also detected in rat fecal extracts after chronic oral dosing [<xref rid="B46-marinedrugs-17-00567" ref-type="bibr">46</xref>]. The in vivo efficacy of GRFT was also demonstrated in the humanized bone marrow-liver-thymus mice which were protected from vaginal infection with HIV-1 after being treated with recombinant <italic>C. crescentus</italic> expressing GRFT [<xref rid="B47-marinedrugs-17-00567" ref-type="bibr">47</xref>]. However, GRFT was not orally bioavailable even after chronic treatment [<xref rid="B46-marinedrugs-17-00567" ref-type="bibr">46</xref>]. </p></sec><sec id="sec9-marinedrugs-17-00567"><title>9. Large-Scale Production</title><p>The clinical application of protein drugs requires a cost-effective large-scale production procedure to meet the high volume needed in a clinical setting. For efficient GRFT production, seven different production methods have been developed and optimized (<xref rid="marinedrugs-17-00567-t008" ref-type="table">Table 8</xref>) [<xref rid="B45-marinedrugs-17-00567" ref-type="bibr">45</xref>,<xref rid="B48-marinedrugs-17-00567" ref-type="bibr">48</xref>,<xref rid="B49-marinedrugs-17-00567" ref-type="bibr">49</xref>,<xref rid="B50-marinedrugs-17-00567" ref-type="bibr">50</xref>,<xref rid="B51-marinedrugs-17-00567" ref-type="bibr">51</xref>,<xref rid="B52-marinedrugs-17-00567" ref-type="bibr">52</xref>,<xref rid="B53-marinedrugs-17-00567" ref-type="bibr">53</xref>]. Giomarelli et al. used a fermenter and a rich, auto-inducing medium, which led to an approximately 45-fold increase in the total amount of GRFT per liter with approximately 70% of the protein expressed in the soluble fraction [<xref rid="B49-marinedrugs-17-00567" ref-type="bibr">49</xref>]. O&#x02019;Keefe et al. were able to produce GRFT in multigram quantities by using <italic>Nicotiana benthamiana</italic> plants transduced with a tobacco mosaic virus vector expressing GRFT [<xref rid="B45-marinedrugs-17-00567" ref-type="bibr">45</xref>]. Hahn et al. employed a simple spraying method to introduce agrobacterium vectors into Nicotiana plants in the presence of a surfactant as a substitute for vacuum inoculation [<xref rid="B50-marinedrugs-17-00567" ref-type="bibr">50</xref>]. They found that recombinant GRFT is stable during the storage of plant biomass as silage, which is suitable for mass production of cost-sensitive products [<xref rid="B50-marinedrugs-17-00567" ref-type="bibr">50</xref>]. Fuqua et al., however, developed a simplified GRFT purification method [<xref rid="B48-marinedrugs-17-00567" ref-type="bibr">48</xref>]. They achieved &#x0003e;99% pure GRFT by generating the initial green juice extract in pH 4 buffer, heating the extract to 55 &#x000b0;C, incubating it overnight with a bentonite MgCl<sub>2</sub> mixture, and purifying it via chromatography [<xref rid="B48-marinedrugs-17-00567" ref-type="bibr">48</xref>]. Vamvaka et al. successfully produced GRFT by using the endosperm of transgenic rice plants (<italic>Oryza sativa</italic>) [<xref rid="B52-marinedrugs-17-00567" ref-type="bibr">52</xref>]. They found that both crude and pure GRFT had potent anti-HIV activity, and the crude extracts were not toxic in human cell lines [<xref rid="B52-marinedrugs-17-00567" ref-type="bibr">52</xref>]. This suggests that crude GRFT with minimal processing could be administered to reduce costs associated with purification [<xref rid="B52-marinedrugs-17-00567" ref-type="bibr">52</xref>]. Petrova et al. expressed GRFT in the probiotic strains <italic>Lactobacillus rhamnosus</italic> GG and <italic>L. rhamnosus</italic> GR-1 for gastrointestinal and vaginal mucosal delivery, respectively [<xref rid="B51-marinedrugs-17-00567" ref-type="bibr">51</xref>]. Hoelscher et al. used stably transformed tobacco chloroplasts to produce GRFT, which accounted for up to 5% of the total soluble protein of the plant [<xref rid="B53-marinedrugs-17-00567" ref-type="bibr">53</xref>]. They also found that the tobacco, when dried, provides a storable source of GRFT that can be purified at a later date [<xref rid="B53-marinedrugs-17-00567" ref-type="bibr">53</xref>]. However, when produced in <italic>Nicotiana benthamiana</italic>, Kim et al. found that GRFT had pathologic effects on plants because it was directed to the apoplast during production, resulting in necrotic symptoms associated with hypersensitive response (HR)-like cell death [<xref rid="B54-marinedrugs-17-00567" ref-type="bibr">54</xref>]. They found that a specific interaction between GRFT and an apoplast-located endogenous glycoprotein, XYL1, initiated the HR response. To suppress GRFT-induced cell death in <italic>Nicotiana benthamiana,</italic> exogenous expression of naphthalene hydroxylase was suggested by the authors [<xref rid="B54-marinedrugs-17-00567" ref-type="bibr">54</xref>]. To avoid the emergence of HIV-1 strains resistant to single microbicides, Vamvaka et al. expressed components of multiple anti-HIV proteins including GRFT, 2G12 mAb, and cyanovirin-N in rice endosperm [<xref rid="B55-marinedrugs-17-00567" ref-type="bibr">55</xref>]. They found that extracts from plants expressing all three proteins showed enhanced in vitro binding to gp120 and synergistic HIV-1 neutralization [<xref rid="B55-marinedrugs-17-00567" ref-type="bibr">55</xref>]. Unexpectedly, they also found that synergistic HIV neutralization caused by the triple microbicide was enhanced by production in rice endosperm because rice globulin protein enhances gp120 binding in the expressed proteins [<xref rid="B55-marinedrugs-17-00567" ref-type="bibr">55</xref>]. </p></sec><sec id="sec10-marinedrugs-17-00567"><title>10. A Formulation for Efficient Delivery</title><p>Protein stability is critical for long-term maintenance of pharmacological activity. For this reason, the susceptibility of GRFT to proteolytic digestion should be considered. GRFT was resistant to digestion by eight different proteases including pepsin, papain, leucine aminopeptidase, pronase, &#x003b1;-chymotrypsin, proteinase K, endoproteinase, and trypsin [<xref rid="B56-marinedrugs-17-00567" ref-type="bibr">56</xref>]. A number of different nanoparticle drug delivery systems have been tested to provide sustained and controlled delivery of GRFT, improve its solubility, protect its payloads, and enhance its mucosal permeability (<xref rid="marinedrugs-17-00567-t009" ref-type="table">Table 9</xref>) [<xref rid="B57-marinedrugs-17-00567" ref-type="bibr">57</xref>,<xref rid="B58-marinedrugs-17-00567" ref-type="bibr">58</xref>,<xref rid="B59-marinedrugs-17-00567" ref-type="bibr">59</xref>,<xref rid="B60-marinedrugs-17-00567" ref-type="bibr">60</xref>]. PLGA (poly lactic-co-glycolic acid) nanoparticles with a diameter of approximately 180&#x02013;200 nm were successfully used in the co-delivery of GRFT and dapivirine in vitro [<xref rid="B60-marinedrugs-17-00567" ref-type="bibr">60</xref>]. Both drugs showed a biphasic release with an initial burst phase followed by a sustained release phase [<xref rid="B60-marinedrugs-17-00567" ref-type="bibr">60</xref>]. Grooms et al. successfully generated GRFT-modified electrospun fibers to inactivate HIV prior to cellular entry [<xref rid="B57-marinedrugs-17-00567" ref-type="bibr">57</xref>]. Furthermore, Lal et al. developed a self-administered, vaginal fast-dissolving insert (FDI) produced by freeze-drying that delivered safe and effective amounts of GRFT and carrageenan (GC), a sulfated polysaccharide extracted from seaweed [<xref rid="B58-marinedrugs-17-00567" ref-type="bibr">58</xref>]. Fibers comprised of methoxy polyethylene glycol-PLGA: poly n-butyl acrylate-co-acrylic acid (mPEG-PLGA: PBA-co-PAA) were able to achieve high GRFT loading. These GRFT-loaded fibers were well maintained within a simulated vaginal fluid (SVF) and showed pH-dependent release upon exposure to buffered SVF and simulated semen solutions [<xref rid="B59-marinedrugs-17-00567" ref-type="bibr">59</xref>]. </p></sec><sec id="sec11-marinedrugs-17-00567"><title>11. Clinical Study</title><p>To date, two phase-one clinical studies have been initiated to investigate the potential toxicity of GRFT in healthy populations [<xref rid="B61-marinedrugs-17-00567" ref-type="bibr">61</xref>,<xref rid="B62-marinedrugs-17-00567" ref-type="bibr">62</xref>]. The first study aimed to evaluate the safety of GRFT in a CG gel used vaginally for a single dose and then for 14 consecutive days in healthy women [<xref rid="B61-marinedrugs-17-00567" ref-type="bibr">61</xref>]. This was a two-part study with the first part consisting of a single-dose and an open-label design, and the second part consisted of a multiple-dose, randomized, placebo-controlled study design. During the second part, 30 subjects were administered a placebo and 30 subjects were given the GRFT gel. In this study, the pharmacokinetic behavior of GRFT was also analyzed by forming a time-concentration curve of GRFT in blood samples. However, rising dose tolerance was not studied because of the minimal systemic absorbance of GRFT, which was reported in preclinical studies. Although the official study results are not available yet, the Population Council website reported GRFT to be safe for vaginal use for up to 14 days with potent anti-HIV activity in cell-based assays and cervical explants up to 8 h after receiving the dose [<xref rid="B63-marinedrugs-17-00567" ref-type="bibr">63</xref>]. In 2014, another phase-one clinical study for GRFT started as an integrated preclinical/clinical program. This program, which was named PREVENT (pre-exposure prevention of viral entry), aimed to provide a comprehensive set of data to facilitate an informed decision on whether GRFT should progress within the topical microbicides pipeline [<xref rid="B62-marinedrugs-17-00567" ref-type="bibr">62</xref>]. This was a randomized, double-blind phase-one safety and pharmacokinetic study of GRFT enema administered rectally to HIV-1 seronegative adults who practice URAI. The number and frequency of adverse events, the blood concentration of GRFT, and changes in humoral antibody response were analyzed. This on-going clinical study will be completed in 2021.</p></sec><sec id="sec12-marinedrugs-17-00567"><title>12. The Antimicrobial Activity of GRFT on Other Viruses</title><p>GRFT not only displays antiviral activity against HIV but also for other enveloped viruses such as SARS-CoV [<xref rid="B10-marinedrugs-17-00567" ref-type="bibr">10</xref>], MERS-CoV [<xref rid="B11-marinedrugs-17-00567" ref-type="bibr">11</xref>], HCV [<xref rid="B12-marinedrugs-17-00567" ref-type="bibr">12</xref>,<xref rid="B13-marinedrugs-17-00567" ref-type="bibr">13</xref>], HSV [<xref rid="B14-marinedrugs-17-00567" ref-type="bibr">14</xref>,<xref rid="B15-marinedrugs-17-00567" ref-type="bibr">15</xref>,<xref rid="B64-marinedrugs-17-00567" ref-type="bibr">64</xref>], JEV [<xref rid="B16-marinedrugs-17-00567" ref-type="bibr">16</xref>,<xref rid="B17-marinedrugs-17-00567" ref-type="bibr">17</xref>], and PEDV [<xref rid="B18-marinedrugs-17-00567" ref-type="bibr">18</xref>]. Even human papillomavirus (HPV), which is a non-enveloped virus, was inactivated by GRFT via a glycosylation-independent mechanism [<xref rid="B15-marinedrugs-17-00567" ref-type="bibr">15</xref>]. GRFT specifically bound to the SARS-CoV spike glycoprotein and inhibited viral entry [<xref rid="B10-marinedrugs-17-00567" ref-type="bibr">10</xref>]. GRFT also inhibited particles pseudotyped with the MERS-CoV spike protein from entering host cells [<xref rid="B11-marinedrugs-17-00567" ref-type="bibr">11</xref>]. Preincubation of HCV particles with GRFT prevented infection of Huh-7 hepatoma cells [<xref rid="B13-marinedrugs-17-00567" ref-type="bibr">13</xref>]. Furthermore, GRFT was able to interfere with the direct cell-to-cell transmission of HCV [<xref rid="B13-marinedrugs-17-00567" ref-type="bibr">13</xref>]. This anti-HCV activity was further demonstrated in vivo when HCV infection was mitigated in chimeric mice [<xref rid="B12-marinedrugs-17-00567" ref-type="bibr">12</xref>]. In this report, GRFT was readily bioavailable after subcutaneous injection, and it showed significant in vivo efficacy by reducing HCV viral titers in a mouse model system with engrafted human hepatocytes [<xref rid="B12-marinedrugs-17-00567" ref-type="bibr">12</xref>]. In contrast to HIV, HCV resistance to GRFT was not directly conferred by mutations in the envelope protein genes, but it could occur through an indirect mechanism involving mutations in other viral proteins [<xref rid="B65-marinedrugs-17-00567" ref-type="bibr">65</xref>]. GRFT displayed modest inhibitory activity against HSV-2 if it was present during viral entry, but if it was present post-entry, it completely blocked plaque formation, reduced plaque size, and prevented cell-to-cell propagation [<xref rid="B14-marinedrugs-17-00567" ref-type="bibr">14</xref>]. These in vitro findings translated into significant protection against genital herpes in mice treated with a 0.1% griffithsin gel [<xref rid="B14-marinedrugs-17-00567" ref-type="bibr">14</xref>]. The in vivo anti-HSV activity of GRFT was further demonstrated when murine model test subjects were protected by <italic>C. crescentus</italic> expressing GRFT after intravaginal infection with HSV-2 [<xref rid="B64-marinedrugs-17-00567" ref-type="bibr">64</xref>]. Levendosky et al. explored the antiviral properties of a combination product composed of GRFT and CG against HSV-2 and HPV. They found that GRFT was able to block the entry of HSV-2 and HPV into target cells but not the adsorption of HSV-2 and HPV onto target cells [<xref rid="B15-marinedrugs-17-00567" ref-type="bibr">15</xref>]. This GRFT/CG combination was also tested as a freeze-dried, FDI formulation. This product protected rhesus macaques against a high-dose vaginal simian HIV challenge 4 h after FDI insertion [<xref rid="B66-marinedrugs-17-00567" ref-type="bibr">66</xref>]. Furthermore, this GRFT/CG FDI also protected mice, vaginally, against HSV-2 and HPV pseudovirus [<xref rid="B66-marinedrugs-17-00567" ref-type="bibr">66</xref>]. In vitro experiments showed that the treatment of JEV with GRFT before inoculation into BHK- 21 cells inhibited infection in a dose-dependent manner [<xref rid="B17-marinedrugs-17-00567" ref-type="bibr">17</xref>]. In vivo experiments showed that GRFT (5 mg/kg) administered intraperitoneally before virus infection prevented mortality in mice challenged intraperitoneally with a lethal dose of JEV [<xref rid="B17-marinedrugs-17-00567" ref-type="bibr">17</xref>]. With regard to its antiviral mechanism, GRFT was shown to bind to JEV glycosylated viral proteins, specifically the enveloped and pre-mature glycoproteins [<xref rid="B16-marinedrugs-17-00567" ref-type="bibr">16</xref>]. In addition, GRFT was able to reduce PEDV infection in Vero cells [<xref rid="B18-marinedrugs-17-00567" ref-type="bibr">18</xref>]. </p></sec><sec sec-type="conclusions" id="sec13-marinedrugs-17-00567"><title>13. Conclusions</title><p>Due to its novel carbohydrate-targeting antiviral mechanism of action, superior anti-HIV-1 efficacy, excellent host toxicity profile, synergistic interaction with other antiretroviral drugs, optimized large-scale production methodology, and various formulation methods for its efficient delivery, GRFT holds great promise as the first topical protein-based anti-HIV pre-exposure prophylactic. Even though a potentially adverse immunotoxicity issue observed during preclinical animal studies needs to be resolved, its broad antiviral spectrum, which is applicable to other enveloped viruses, could make GRFT the first universal antiviral therapeutic that can specifically target virus carbohydrates. Favorable outcomes from two ongoing phase-one clinical trials will accelerate the drug development process. If approved, GRFT will provide a superior way to prevent many transmissible viral infections.</p></sec></body><back><notes><title>Funding</title><p>This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (NRF-2019R1F1A1058628). </p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The author declares that there are no competing interests regarding the publication of this paper.</p></notes><ref-list><title>References</title><ref id="B1-marinedrugs-17-00567"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swanson</surname><given-names>M.D.</given-names></name><name><surname>Winter</surname><given-names>H.C.</given-names></name><name><surname>Goldstein</surname><given-names>I.J.</given-names></name><name><surname>Markovitz</surname><given-names>D.M.</given-names></name></person-group><article-title>A lectin isolated from bananas is a potent inhibitor of HIV replication</article-title><source>J. Biol. Chem.</source><year>2010</year><volume>285</volume><fpage>8646</fpage><lpage>8655</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.034926</pub-id><?supplied-pmid 20080975?><pub-id pub-id-type="pmid">20080975</pub-id></element-citation></ref><ref id="B2-marinedrugs-17-00567"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Keefe</surname><given-names>B.R.</given-names></name><name><surname>Smee</surname><given-names>D.F.</given-names></name><name><surname>Turpin</surname><given-names>J.A.</given-names></name><name><surname>Saucedo</surname><given-names>C.J.</given-names></name><name><surname>Gustafson</surname><given-names>K.R.</given-names></name><name><surname>Mori</surname><given-names>T.</given-names></name><name><surname>Blakeslee</surname><given-names>D.</given-names></name><name><surname>Buckheit</surname><given-names>R.</given-names></name><name><surname>Boyd</surname><given-names>M.R.</given-names></name></person-group><article-title>Potent anti-influenza activity of cyanovirin-n and interactions with viral hemagglutinin</article-title><source>Antimicrobial. Agents Chemother.</source><year>2003</year><volume>47</volume><fpage>2518</fpage><lpage>2525</lpage><pub-id pub-id-type="doi">10.1128/AAC.47.8.2518-2525.2003</pub-id><?supplied-pmid 12878514?><pub-id pub-id-type="pmid">12878514</pub-id></element-citation></ref><ref id="B3-marinedrugs-17-00567"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huskens</surname><given-names>D.</given-names></name><name><surname>Ferir</surname><given-names>G.</given-names></name><name><surname>Vermeire</surname><given-names>K.</given-names></name><name><surname>Kehr</surname><given-names>J.C.</given-names></name><name><surname>Balzarini</surname><given-names>J.</given-names></name><name><surname>Dittmann</surname><given-names>E.</given-names></name><name><surname>Schols</surname><given-names>D.</given-names></name></person-group><article-title>Microvirin, a novel alpha(1,2)-mannose-specific lectin isolated from microcystis aeruginosa, has anti-HIV-1 activity comparable with that of cyanovirin-n but a much higher safety profile</article-title><source>J. Biol. Chem.</source><year>2010</year><volume>285</volume><fpage>24845</fpage><lpage>24854</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.128546</pub-id><?supplied-pmid 20507987?><pub-id pub-id-type="pmid">20507987</pub-id></element-citation></ref><ref id="B4-marinedrugs-17-00567"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janahi</surname><given-names>E.M.A.</given-names></name><name><surname>Haque</surname><given-names>S.</given-names></name><name><surname>Akhter</surname><given-names>N.</given-names></name><name><surname>Wahid</surname><given-names>M.</given-names></name><name><surname>Jawed</surname><given-names>A.</given-names></name><name><surname>Mandal</surname><given-names>R.K.</given-names></name><name><surname>Lohani</surname><given-names>M.</given-names></name><name><surname>Areeshi</surname><given-names>M.Y.</given-names></name><name><surname>Almalki</surname><given-names>S.</given-names></name><name><surname>Das</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Bioengineered intravaginal isolate of lactobacillus plantarum expresses algal lectin scytovirin demonstrating anti-HIV-1 activity</article-title><source>Microb. Pathog.</source><year>2018</year><volume>122</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.micpath.2018.06.002</pub-id><?supplied-pmid 29870744?><pub-id pub-id-type="pmid">29870744</pub-id></element-citation></ref><ref id="B5-marinedrugs-17-00567"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>T.</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>B.R.</given-names></name><name><surname>Sowder</surname><given-names>R.C.</given-names><suffix>2nd</suffix></name><name><surname>Bringans</surname><given-names>S.</given-names></name><name><surname>Gardella</surname><given-names>R.</given-names></name><name><surname>Berg</surname><given-names>S.</given-names></name><name><surname>Cochran</surname><given-names>P.</given-names></name><name><surname>Turpin</surname><given-names>J.A.</given-names></name><name><surname>Buckheit</surname><given-names>R.W.</given-names><suffix>Jr.</suffix></name><name><surname>McMahon</surname><given-names>J.B.</given-names></name><etal/></person-group><article-title>Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga <italic>Griffithsia</italic> sp.</article-title><source>J. Biol. Chem.</source><year>2005</year><volume>280</volume><fpage>9345</fpage><lpage>9353</lpage><pub-id pub-id-type="doi">10.1074/jbc.M411122200</pub-id><?supplied-pmid 15613479?><pub-id pub-id-type="pmid">15613479</pub-id></element-citation></ref><ref id="B6-marinedrugs-17-00567"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>A.</given-names></name></person-group><article-title>Toxicity of antiretroviral therapy and implications for drug development</article-title><source>Nat. Rev. Drug Discov.</source><year>2003</year><volume>2</volume><fpage>624</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1038/nrd1151</pub-id><pub-id pub-id-type="pmid">12904812</pub-id></element-citation></ref><ref id="B7-marinedrugs-17-00567"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdool Karim</surname><given-names>Q.</given-names></name><name><surname>Abdool Karim</surname><given-names>S.S.</given-names></name><name><surname>Frohlich</surname><given-names>J.A.</given-names></name><name><surname>Grobler</surname><given-names>A.C.</given-names></name><name><surname>Baxter</surname><given-names>C.</given-names></name><name><surname>Mansoor</surname><given-names>L.E.</given-names></name><name><surname>Kharsany</surname><given-names>A.B.</given-names></name><name><surname>Sibeko</surname><given-names>S.</given-names></name><name><surname>Mlisana</surname><given-names>K.P.</given-names></name><name><surname>Omar</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women</article-title><source>Science</source><year>2010</year><volume>329</volume><fpage>1168</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1126/science.1193748</pub-id><pub-id pub-id-type="pmid">20643915</pub-id></element-citation></ref><ref id="B8-marinedrugs-17-00567"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beyrer</surname><given-names>C.</given-names></name><name><surname>Baral</surname><given-names>S.D.</given-names></name><name><surname>van Griensven</surname><given-names>F.</given-names></name><name><surname>Goodreau</surname><given-names>S.M.</given-names></name><name><surname>Chariyalertsak</surname><given-names>S.</given-names></name><name><surname>Wirtz</surname><given-names>A.L.</given-names></name><name><surname>Brookmeyer</surname><given-names>R.</given-names></name></person-group><article-title>Global epidemiology of HIV infection in men who have sex with men</article-title><source>Lancet</source><year>2012</year><volume>380</volume><fpage>367</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)60821-6</pub-id><pub-id pub-id-type="pmid">22819660</pub-id></element-citation></ref><ref id="B9-marinedrugs-17-00567"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lusvarghi</surname><given-names>S.</given-names></name><name><surname>Bewley</surname><given-names>C.A.</given-names></name></person-group><article-title>Griffithsin: An antiviral lectin with outstanding therapeutic potential</article-title><source>Viruses</source><year>2016</year><volume>8</volume><elocation-id>296</elocation-id><pub-id pub-id-type="doi">10.3390/v8100296</pub-id></element-citation></ref><ref id="B10-marinedrugs-17-00567"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Keefe</surname><given-names>B.R.</given-names></name><name><surname>Giomarelli</surname><given-names>B.</given-names></name><name><surname>Barnard</surname><given-names>D.L.</given-names></name><name><surname>Shenoy</surname><given-names>S.R.</given-names></name><name><surname>Chan</surname><given-names>P.K.</given-names></name><name><surname>McMahon</surname><given-names>J.B.</given-names></name><name><surname>Palmer</surname><given-names>K.E.</given-names></name><name><surname>Barnett</surname><given-names>B.W.</given-names></name><name><surname>Meyerholz</surname><given-names>D.K.</given-names></name><name><surname>Wohlford-Lenane</surname><given-names>C.L.</given-names></name><etal/></person-group><article-title>Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family coronaviridae</article-title><source>J. Virol.</source><year>2010</year><volume>84</volume><fpage>2511</fpage><lpage>2521</lpage><pub-id pub-id-type="doi">10.1128/JVI.02322-09</pub-id><pub-id pub-id-type="pmid">20032190</pub-id></element-citation></ref><ref id="B11-marinedrugs-17-00567"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millet</surname><given-names>J.K.</given-names></name><name><surname>Seron</surname><given-names>K.</given-names></name><name><surname>Labitt</surname><given-names>R.N.</given-names></name><name><surname>Danneels</surname><given-names>A.</given-names></name><name><surname>Palmer</surname><given-names>K.E.</given-names></name><name><surname>Whittaker</surname><given-names>G.R.</given-names></name><name><surname>Dubuisson</surname><given-names>J.</given-names></name><name><surname>Belouzard</surname><given-names>S.</given-names></name></person-group><article-title>Middle east respiratory syndrome coronavirus infection is inhibited by griffithsin</article-title><source>Antiviral Res.</source><year>2016</year><volume>133</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2016.07.011</pub-id><?supplied-pmid 27424494?><pub-id pub-id-type="pmid">27424494</pub-id></element-citation></ref><ref id="B12-marinedrugs-17-00567"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takebe</surname><given-names>Y.</given-names></name><name><surname>Saucedo</surname><given-names>C.J.</given-names></name><name><surname>Lund</surname><given-names>G.</given-names></name><name><surname>Uenishi</surname><given-names>R.</given-names></name><name><surname>Hase</surname><given-names>S.</given-names></name><name><surname>Tsuchiura</surname><given-names>T.</given-names></name><name><surname>Kneteman</surname><given-names>N.</given-names></name><name><surname>Ramessar</surname><given-names>K.</given-names></name><name><surname>Tyrrell</surname><given-names>D.L.</given-names></name><name><surname>Shirakura</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Antiviral lectins from red and blue-green algae show potent in vitro and in vivo activity against hepatitis c virus</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e64449</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0064449</pub-id><?supplied-pmid 23700478?><pub-id pub-id-type="pmid">23700478</pub-id></element-citation></ref><ref id="B13-marinedrugs-17-00567"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meuleman</surname><given-names>P.</given-names></name><name><surname>Albecka</surname><given-names>A.</given-names></name><name><surname>Belouzard</surname><given-names>S.</given-names></name><name><surname>Vercauteren</surname><given-names>K.</given-names></name><name><surname>Verhoye</surname><given-names>L.</given-names></name><name><surname>Wychowski</surname><given-names>C.</given-names></name><name><surname>Leroux-Roels</surname><given-names>G.</given-names></name><name><surname>Palmer</surname><given-names>K.E.</given-names></name><name><surname>Dubuisson</surname><given-names>J.</given-names></name></person-group><article-title>Griffithsin has antiviral activity against hepatitis C virus</article-title><source>Antimicrob. Agents Chemother.</source><year>2011</year><volume>55</volume><fpage>5159</fpage><lpage>5167</lpage><pub-id pub-id-type="doi">10.1128/AAC.00633-11</pub-id><?supplied-pmid 21896910?><pub-id pub-id-type="pmid">21896910</pub-id></element-citation></ref><ref id="B14-marinedrugs-17-00567"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nixon</surname><given-names>B.</given-names></name><name><surname>Stefanidou</surname><given-names>M.</given-names></name><name><surname>Mesquita</surname><given-names>P.M.</given-names></name><name><surname>Fakioglu</surname><given-names>E.</given-names></name><name><surname>Segarra</surname><given-names>T.</given-names></name><name><surname>Rohan</surname><given-names>L.</given-names></name><name><surname>Halford</surname><given-names>W.</given-names></name><name><surname>Palmer</surname><given-names>K.E.</given-names></name><name><surname>Herold</surname><given-names>B.C.</given-names></name></person-group><article-title>Griffithsin protects mice from genital herpes by preventing cell-to-cell spread</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>6257</fpage><lpage>6269</lpage><pub-id pub-id-type="doi">10.1128/JVI.00012-13</pub-id><?supplied-pmid 23536670?><pub-id pub-id-type="pmid">23536670</pub-id></element-citation></ref><ref id="B15-marinedrugs-17-00567"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levendosky</surname><given-names>K.</given-names></name><name><surname>Mizenina</surname><given-names>O.</given-names></name><name><surname>Martinelli</surname><given-names>E.</given-names></name><name><surname>Jean-Pierre</surname><given-names>N.</given-names></name><name><surname>Kizima</surname><given-names>L.</given-names></name><name><surname>Rodriguez</surname><given-names>A.</given-names></name><name><surname>Kleinbeck</surname><given-names>K.</given-names></name><name><surname>Bonnaire</surname><given-names>T.</given-names></name><name><surname>Robbiani</surname><given-names>M.</given-names></name><name><surname>Zydowsky</surname><given-names>T.M.</given-names></name><etal/></person-group><article-title>Griffithsin and carrageenan combination to target herpes simplex virus 2 and human papillomavirus</article-title><source>Antimicrob. Agents Chemother.</source><year>2015</year><volume>59</volume><fpage>7290</fpage><lpage>7298</lpage><pub-id pub-id-type="doi">10.1128/AAC.01816-15</pub-id><pub-id pub-id-type="pmid">26369967</pub-id></element-citation></ref><ref id="B16-marinedrugs-17-00567"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishag</surname><given-names>H.Z.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Mao</surname><given-names>X.</given-names></name></person-group><article-title>Griffithsin binds to the glycosylated proteins (E and prM) of japanese encephalitis virus and inhibit its infection</article-title><source>Virus Res.</source><year>2016</year><volume>215</volume><fpage>50</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2016.01.016</pub-id><pub-id pub-id-type="pmid">26820432</pub-id></element-citation></ref><ref id="B17-marinedrugs-17-00567"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishag</surname><given-names>H.Z.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>M.X.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Ni</surname><given-names>B.</given-names></name><name><surname>Malik</surname><given-names>T.</given-names></name><name><surname>Chen</surname><given-names>P.Y.</given-names></name><name><surname>Mao</surname><given-names>X.</given-names></name></person-group><article-title>Griffithsin inhibits japanese encephalitis virus infection in vitro and in vivo</article-title><source>Arch. Virol.</source><year>2013</year><volume>158</volume><fpage>349</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1007/s00705-012-1489-2</pub-id><pub-id pub-id-type="pmid">23053519</pub-id></element-citation></ref><ref id="B18-marinedrugs-17-00567"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Cheng</surname><given-names>H.</given-names></name><name><surname>Hou</surname><given-names>L.</given-names></name><name><surname>Zheng</surname><given-names>Q.</given-names></name><name><surname>Hou</surname><given-names>J.</given-names></name></person-group><article-title>In vitro antiviral activity of griffithsin against porcine epidemic diarrhea virus</article-title><source>Virus Genes</source><year>2019</year><volume>55</volume><fpage>174</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1007/s11262-019-01633-7</pub-id><pub-id pub-id-type="pmid">30637608</pub-id></element-citation></ref><ref id="B19-marinedrugs-17-00567"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziolkowska</surname><given-names>N.E.</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>B.R.</given-names></name><name><surname>Mori</surname><given-names>T.</given-names></name><name><surname>Zhu</surname><given-names>C.</given-names></name><name><surname>Giomarelli</surname><given-names>B.</given-names></name><name><surname>Vojdani</surname><given-names>F.</given-names></name><name><surname>Palmer</surname><given-names>K.E.</given-names></name><name><surname>McMahon</surname><given-names>J.B.</given-names></name><name><surname>Wlodawer</surname><given-names>A.</given-names></name></person-group><article-title>Domain-swapped structure of the potent antiviral protein griffithsin and its mode of carbohydrate binding</article-title><source>Structure</source><year>2006</year><volume>14</volume><fpage>1127</fpage><lpage>1135</lpage><pub-id pub-id-type="doi">10.1016/j.str.2006.05.017</pub-id><pub-id pub-id-type="pmid">16843894</pub-id></element-citation></ref><ref id="B20-marinedrugs-17-00567"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moulaei</surname><given-names>T.</given-names></name><name><surname>Shenoy</surname><given-names>S.R.</given-names></name><name><surname>Giomarelli</surname><given-names>B.</given-names></name><name><surname>Thomas</surname><given-names>C.</given-names></name><name><surname>McMahon</surname><given-names>J.B.</given-names></name><name><surname>Dauter</surname><given-names>Z.</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>B.R.</given-names></name><name><surname>Wlodawer</surname><given-names>A.</given-names></name></person-group><article-title>Monomerization of viral entry inhibitor griffithsin elucidates the relationship between multivalent binding to carbohydrates and anti-HIV activity</article-title><source>Structure</source><year>2010</year><volume>18</volume><fpage>1104</fpage><lpage>1115</lpage><pub-id pub-id-type="doi">10.1016/j.str.2010.05.016</pub-id><pub-id pub-id-type="pmid">20826337</pub-id></element-citation></ref><ref id="B21-marinedrugs-17-00567"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>J.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Hoorelbeke</surname><given-names>B.</given-names></name><name><surname>Kagiampakis</surname><given-names>I.</given-names></name><name><surname>Zhao</surname><given-names>B.</given-names></name><name><surname>Demeler</surname><given-names>B.</given-names></name><name><surname>Balzarini</surname><given-names>J.</given-names></name><name><surname>Liwang</surname><given-names>P.J.</given-names></name></person-group><article-title>The role of individual carbohydrate-binding sites in the function of the potent anti-HIV lectin griffithsin</article-title><source>Mol. Pharm.</source><year>2012</year><volume>9</volume><fpage>2613</fpage><lpage>2625</lpage><pub-id pub-id-type="doi">10.1021/mp300194b</pub-id><?supplied-pmid 22827601?><pub-id pub-id-type="pmid">22827601</pub-id></element-citation></ref><ref id="B22-marinedrugs-17-00567"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziolkowska</surname><given-names>N.E.</given-names></name><name><surname>Shenoy</surname><given-names>S.R.</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>B.R.</given-names></name><name><surname>McMahon</surname><given-names>J.B.</given-names></name><name><surname>Palmer</surname><given-names>K.E.</given-names></name><name><surname>Dwek</surname><given-names>R.A.</given-names></name><name><surname>Wormald</surname><given-names>M.R.</given-names></name><name><surname>Wlodawer</surname><given-names>A.</given-names></name></person-group><article-title>Crystallographic, thermodynamic, and molecular modeling studies of the mode of binding of oligosaccharides to the potent antiviral protein griffithsin</article-title><source>Proteins</source><year>2007</year><volume>67</volume><fpage>661</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1002/prot.21336</pub-id><?supplied-pmid 17340634?><pub-id pub-id-type="pmid">17340634</pub-id></element-citation></ref><ref id="B23-marinedrugs-17-00567"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziolkowska</surname><given-names>N.E.</given-names></name><name><surname>Shenoy</surname><given-names>S.R.</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>B.R.</given-names></name><name><surname>Wlodawer</surname><given-names>A.</given-names></name></person-group><article-title>Crystallographic studies of the complexes of antiviral protein griffithsin with glucose and n-acetylglucosamine</article-title><source>Protein Sci.</source><year>2007</year><volume>16</volume><fpage>1485</fpage><lpage>1489</lpage><pub-id pub-id-type="doi">10.1110/ps.072889407</pub-id><?supplied-pmid 17567736?><pub-id pub-id-type="pmid">17567736</pub-id></element-citation></ref><ref id="B24-marinedrugs-17-00567"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Micewicz</surname><given-names>E.D.</given-names></name><name><surname>Cole</surname><given-names>A.L.</given-names></name><name><surname>Jung</surname><given-names>C.L.</given-names></name><name><surname>Luong</surname><given-names>H.</given-names></name><name><surname>Phillips</surname><given-names>M.L.</given-names></name><name><surname>Pratikhya</surname><given-names>P.</given-names></name><name><surname>Sharma</surname><given-names>S.</given-names></name><name><surname>Waring</surname><given-names>A.J.</given-names></name><name><surname>Cole</surname><given-names>A.M.</given-names></name><name><surname>Ruchala</surname><given-names>P.</given-names></name></person-group><article-title>Grifonin-1: A small HIV-1 entry inhibitor derived from the algal lectin, griffithsin</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><elocation-id>e14360</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0014360</pub-id><?supplied-pmid 21179548?><pub-id pub-id-type="pmid">21179548</pub-id></element-citation></ref><ref id="B25-marinedrugs-17-00567"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandre</surname><given-names>K.B.</given-names></name><name><surname>Gray</surname><given-names>E.S.</given-names></name><name><surname>Lambson</surname><given-names>B.E.</given-names></name><name><surname>Moore</surname><given-names>P.L.</given-names></name><name><surname>Choge</surname><given-names>I.A.</given-names></name><name><surname>Mlisana</surname><given-names>K.</given-names></name><name><surname>Karim</surname><given-names>S.S.</given-names></name><name><surname>McMahon</surname><given-names>J.</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>B.</given-names></name><name><surname>Chikwamba</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Mannose-rich glycosylation patterns on HIV-1 subtype c gp120 and sensitivity to the lectins, griffithsin, cyanovirin-n and scytovirin</article-title><source>Virology</source><year>2010</year><volume>402</volume><fpage>187</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2010.03.021</pub-id><pub-id pub-id-type="pmid">20392471</pub-id></element-citation></ref><ref id="B26-marinedrugs-17-00567"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandre</surname><given-names>K.B.</given-names></name><name><surname>Gray</surname><given-names>E.S.</given-names></name><name><surname>Pantophlet</surname><given-names>R.</given-names></name><name><surname>Moore</surname><given-names>P.L.</given-names></name><name><surname>McMahon</surname><given-names>J.B.</given-names></name><name><surname>Chakauya</surname><given-names>E.</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>B.R.</given-names></name><name><surname>Chikwamba</surname><given-names>R.</given-names></name><name><surname>Morris</surname><given-names>L.</given-names></name></person-group><article-title>Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site</article-title><source>J. Virol.</source><year>2011</year><volume>85</volume><fpage>9039</fpage><lpage>9050</lpage><pub-id pub-id-type="doi">10.1128/JVI.02675-10</pub-id><pub-id pub-id-type="pmid">21697467</pub-id></element-citation></ref><ref id="B27-marinedrugs-17-00567"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emau</surname><given-names>P.</given-names></name><name><surname>Tian</surname><given-names>B.</given-names></name><name><surname>O&#x02019;Keefe B</surname><given-names>R.</given-names></name><name><surname>Mori</surname><given-names>T.</given-names></name><name><surname>McMahon</surname><given-names>J.B.</given-names></name><name><surname>Palmer</surname><given-names>K.E.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Bekele</surname><given-names>G.</given-names></name><name><surname>Tsai</surname><given-names>C.C.</given-names></name></person-group><article-title>Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide</article-title><source>J. Med. Primatol.</source><year>2007</year><volume>36</volume><fpage>244</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0684.2007.00242.x</pub-id><pub-id pub-id-type="pmid">17669213</pub-id></element-citation></ref><ref id="B28-marinedrugs-17-00567"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferir</surname><given-names>G.</given-names></name><name><surname>Huskens</surname><given-names>D.</given-names></name><name><surname>Palmer</surname><given-names>K.E.</given-names></name><name><surname>Boudreaux</surname><given-names>D.M.</given-names></name><name><surname>Swanson</surname><given-names>M.D.</given-names></name><name><surname>Markovitz</surname><given-names>D.M.</given-names></name><name><surname>Balzarini</surname><given-names>J.</given-names></name><name><surname>Schols</surname><given-names>D.</given-names></name></person-group><article-title>Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV type 1, HIV type 2, and selected carbohydrate-binding agent-resistant HIV type 1 strains</article-title><source>AIDS Res. Hum. Retroviruses</source><year>2012</year><volume>28</volume><fpage>1513</fpage><lpage>1523</lpage><pub-id pub-id-type="doi">10.1089/aid.2012.0026</pub-id><pub-id pub-id-type="pmid">22607556</pub-id></element-citation></ref><ref id="B29-marinedrugs-17-00567"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferir</surname><given-names>G.</given-names></name><name><surname>Palmer</surname><given-names>K.E.</given-names></name><name><surname>Schols</surname><given-names>D.</given-names></name></person-group><article-title>Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade c</article-title><source>Virology</source><year>2011</year><volume>417</volume><fpage>253</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2011.07.004</pub-id><pub-id pub-id-type="pmid">21802104</pub-id></element-citation></ref><ref id="B30-marinedrugs-17-00567"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoorelbeke</surname><given-names>B.</given-names></name><name><surname>Xue</surname><given-names>J.</given-names></name><name><surname>LiWang</surname><given-names>P.J.</given-names></name><name><surname>Balzarini</surname><given-names>J.</given-names></name></person-group><article-title>Role of the carbohydrate-binding sites of griffithsin in the prevention of DC-SIGN-mediated capture and transmission of HIV-1</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e64132</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0064132</pub-id><pub-id pub-id-type="pmid">23741304</pub-id></element-citation></ref><ref id="B31-marinedrugs-17-00567"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Du</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Luo</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>Q.</given-names></name></person-group><article-title>Sensitivity of transmitted and founder human immunodeficiency virus type 1 envelopes to carbohydrate-binding agents griffithsin, cyanovirin-n and galanthus nivalis agglutinin</article-title><source>J. Gen. Virol.</source><year>2015</year><volume>96</volume><fpage>3660</fpage><lpage>3666</lpage><pub-id pub-id-type="doi">10.1099/jgv.0.000299</pub-id><?supplied-pmid 26407826?><pub-id pub-id-type="pmid">26407826</pub-id></element-citation></ref><ref id="B32-marinedrugs-17-00567"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kagiampakis</surname><given-names>I.</given-names></name><name><surname>Gharibi</surname><given-names>A.</given-names></name><name><surname>Mankowski</surname><given-names>M.K.</given-names></name><name><surname>Snyder</surname><given-names>B.A.</given-names></name><name><surname>Ptak</surname><given-names>R.G.</given-names></name><name><surname>Alatas</surname><given-names>K.</given-names></name><name><surname>LiWang</surname><given-names>P.J.</given-names></name></person-group><article-title>Potent strategy to inhibit HIV-1 by binding both gp120 and gp41</article-title><source>Antimicrob. Agents Chemother.</source><year>2011</year><volume>55</volume><fpage>264</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1128/AAC.00376-10</pub-id><?supplied-pmid 20956603?><pub-id pub-id-type="pmid">20956603</pub-id></element-citation></ref><ref id="B33-marinedrugs-17-00567"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferir</surname><given-names>G.</given-names></name><name><surname>Palmer</surname><given-names>K.E.</given-names></name><name><surname>Schols</surname><given-names>D.</given-names></name></person-group><article-title>Griffithsin, alone and combined with all classes of antiretroviral drugs, potently inhibits HIV cell-cell transmission and destruction of CD4+ T cells</article-title><source>Antivir. Antiretrovir.</source><year>2012</year><volume>4</volume><fpage>103</fpage><pub-id pub-id-type="doi">10.4172/jaa.1000054</pub-id></element-citation></ref><ref id="B34-marinedrugs-17-00567"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>K.</given-names></name><name><surname>Michael</surname><given-names>E.</given-names></name><name><surname>Eggink</surname><given-names>D.</given-names></name><name><surname>van Montfort</surname><given-names>T.</given-names></name><name><surname>Lasnik</surname><given-names>A.B.</given-names></name><name><surname>Palmer</surname><given-names>K.E.</given-names></name><name><surname>Sanders</surname><given-names>R.W.</given-names></name><name><surname>Moore</surname><given-names>J.P.</given-names></name><name><surname>Klasse</surname><given-names>P.J.</given-names></name></person-group><article-title>Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice</article-title><source>AIDS Res. Hum. Retroviruses</source><year>2012</year><volume>28</volume><fpage>206</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1089/aid.2011.0101</pub-id><?supplied-pmid 21793733?><pub-id pub-id-type="pmid">21793733</pub-id></element-citation></ref><ref id="B35-marinedrugs-17-00567"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lusvarghi</surname><given-names>S.</given-names></name><name><surname>Lohith</surname><given-names>K.</given-names></name><name><surname>Morin-Leisk</surname><given-names>J.</given-names></name><name><surname>Ghirlando</surname><given-names>R.</given-names></name><name><surname>Hinshaw</surname><given-names>J.E.</given-names></name><name><surname>Bewley</surname><given-names>C.A.</given-names></name></person-group><article-title>Binding site geometry and subdomain valency control effects of neutralizing lectins on HIV-1 viral particles</article-title><source>ACS Infect. Dis</source><year>2016</year><volume>2</volume><fpage>882</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.6b00139</pub-id><?supplied-pmid 27669574?><pub-id pub-id-type="pmid">27669574</pub-id></element-citation></ref><ref id="B36-marinedrugs-17-00567"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moulaei</surname><given-names>T.</given-names></name><name><surname>Alexandre</surname><given-names>K.B.</given-names></name><name><surname>Shenoy</surname><given-names>S.R.</given-names></name><name><surname>Meyerson</surname><given-names>J.R.</given-names></name><name><surname>Krumpe</surname><given-names>L.R.</given-names></name><name><surname>Constantine</surname><given-names>B.</given-names></name><name><surname>Wilson</surname><given-names>J.</given-names></name><name><surname>Buckheit</surname><given-names>R.W.</given-names><suffix>Jr.</suffix></name><name><surname>McMahon</surname><given-names>J.B.</given-names></name><name><surname>Subramaniam</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Griffithsin tandemers: Flexible and potent lectin inhibitors of the human immunodeficiency virus</article-title><source>Retrovirology</source><year>2015</year><volume>12</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.1186/s12977-014-0127-3</pub-id><pub-id pub-id-type="pmid">25613831</pub-id></element-citation></ref><ref id="B37-marinedrugs-17-00567"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>J.</given-names></name><name><surname>Hoorelbeke</surname><given-names>B.</given-names></name><name><surname>Kagiampakis</surname><given-names>I.</given-names></name><name><surname>Demeler</surname><given-names>B.</given-names></name><name><surname>Balzarini</surname><given-names>J.</given-names></name><name><surname>Liwang</surname><given-names>P.J.</given-names></name></person-group><article-title>The griffithsin dimer is required for high-potency inhibition of HIV-1: Evidence for manipulation of the structure of gp120 as part of the griffithsin dimer mechanism</article-title><source>Antimicrob. Agents Chemother.</source><year>2013</year><volume>57</volume><fpage>3976</fpage><lpage>3989</lpage><pub-id pub-id-type="doi">10.1128/AAC.00332-13</pub-id><pub-id pub-id-type="pmid">23752505</pub-id></element-citation></ref><ref id="B38-marinedrugs-17-00567"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandre</surname><given-names>K.B.</given-names></name><name><surname>Gray</surname><given-names>E.S.</given-names></name><name><surname>Mufhandu</surname><given-names>H.</given-names></name><name><surname>McMahon</surname><given-names>J.B.</given-names></name><name><surname>Chakauya</surname><given-names>E.</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>B.R.</given-names></name><name><surname>Chikwamba</surname><given-names>R.</given-names></name><name><surname>Morris</surname><given-names>L.</given-names></name></person-group><article-title>The lectins griffithsin, cyanovirin-n and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4(+) cells</article-title><source>Virology</source><year>2012</year><volume>423</volume><fpage>175</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2011.12.001</pub-id><pub-id pub-id-type="pmid">22209231</pub-id></element-citation></ref><ref id="B39-marinedrugs-17-00567"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandre</surname><given-names>K.B.</given-names></name><name><surname>Moore</surname><given-names>P.L.</given-names></name><name><surname>Nonyane</surname><given-names>M.</given-names></name><name><surname>Gray</surname><given-names>E.S.</given-names></name><name><surname>Ranchobe</surname><given-names>N.</given-names></name><name><surname>Chakauya</surname><given-names>E.</given-names></name><name><surname>McMahon</surname><given-names>J.B.</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>B.R.</given-names></name><name><surname>Chikwamba</surname><given-names>R.</given-names></name><name><surname>Morris</surname><given-names>L.</given-names></name></person-group><article-title>Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN</article-title><source>Virology</source><year>2013</year><volume>446</volume><fpage>66</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2013.07.019</pub-id><pub-id pub-id-type="pmid">24074568</pub-id></element-citation></ref><ref id="B40-marinedrugs-17-00567"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Jin</surname><given-names>W.</given-names></name><name><surname>Griffin</surname><given-names>G.E.</given-names></name><name><surname>Shattock</surname><given-names>R.J.</given-names></name><name><surname>Hu</surname><given-names>Q.</given-names></name></person-group><article-title>Removal of two high-mannose N-linked glycans on gp120 renders human immunodeficiency virus 1 largely resistant to the carbohydrate-binding agent griffithsin</article-title><source>J. Gen. Virol.</source><year>2011</year><volume>92</volume><fpage>2367</fpage><lpage>2373</lpage><pub-id pub-id-type="doi">10.1099/vir.0.033092-0</pub-id><pub-id pub-id-type="pmid">21715597</pub-id></element-citation></ref><ref id="B41-marinedrugs-17-00567"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barton</surname><given-names>C.</given-names></name><name><surname>Kouokam</surname><given-names>J.C.</given-names></name><name><surname>Lasnik</surname><given-names>A.B.</given-names></name><name><surname>Foreman</surname><given-names>O.</given-names></name><name><surname>Cambon</surname><given-names>A.</given-names></name><name><surname>Brock</surname><given-names>G.</given-names></name><name><surname>Montefiori</surname><given-names>D.C.</given-names></name><name><surname>Vojdani</surname><given-names>F.</given-names></name><name><surname>McCormick</surname><given-names>A.A.</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>B.R.</given-names></name><etal/></person-group><article-title>Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models</article-title><source>Antimicrob. Agents Chemother.</source><year>2014</year><volume>58</volume><fpage>120</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1128/AAC.01407-13</pub-id><?supplied-pmid 24145548?><pub-id pub-id-type="pmid">24145548</pub-id></element-citation></ref><ref id="B42-marinedrugs-17-00567"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girard</surname><given-names>L.</given-names></name><name><surname>Birse</surname><given-names>K.</given-names></name><name><surname>Holm</surname><given-names>J.B.</given-names></name><name><surname>Gajer</surname><given-names>P.</given-names></name><name><surname>Humphrys</surname><given-names>M.S.</given-names></name><name><surname>Garber</surname><given-names>D.</given-names></name><name><surname>Guenthner</surname><given-names>P.</given-names></name><name><surname>Noel-Romas</surname><given-names>L.</given-names></name><name><surname>Abou</surname><given-names>M.</given-names></name><name><surname>McCorrister</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Impact of the griffithsin anti-HIV microbicide and placebo gels on the rectal mucosal proteome and microbiome in non-human primates</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>8059</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-26313-8</pub-id><?supplied-pmid 29795295?><pub-id pub-id-type="pmid">29795295</pub-id></element-citation></ref><ref id="B43-marinedrugs-17-00567"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kouokam</surname><given-names>J.C.</given-names></name><name><surname>Huskens</surname><given-names>D.</given-names></name><name><surname>Schols</surname><given-names>D.</given-names></name><name><surname>Johannemann</surname><given-names>A.</given-names></name><name><surname>Riedell</surname><given-names>S.K.</given-names></name><name><surname>Walter</surname><given-names>W.</given-names></name><name><surname>Walker</surname><given-names>J.M.</given-names></name><name><surname>Matoba</surname><given-names>N.</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>B.R.</given-names></name><name><surname>Palmer</surname><given-names>K.E.</given-names></name></person-group><article-title>Investigation of griffithsin&#x02019;s interactions with human cells confirms its outstanding safety and efficacy profile as a microbicide candidate</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e22635</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0022635</pub-id><?supplied-pmid 21829638?><pub-id pub-id-type="pmid">21829638</pub-id></element-citation></ref><ref id="B44-marinedrugs-17-00567"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kouokam</surname><given-names>J.C.</given-names></name><name><surname>Lasnik</surname><given-names>A.B.</given-names></name><name><surname>Palmer</surname><given-names>K.E.</given-names></name></person-group><article-title>Studies in a murine model confirm the safety of griffithsin and advocate its further development as a microbicide targeting HIV-1 and other enveloped viruses</article-title><source>Viruses</source><year>2016</year><volume>8</volume><elocation-id>331</elocation-id><pub-id pub-id-type="doi">10.3390/v8110311</pub-id></element-citation></ref><ref id="B45-marinedrugs-17-00567"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Keefe</surname><given-names>B.R.</given-names></name><name><surname>Vojdani</surname><given-names>F.</given-names></name><name><surname>Buffa</surname><given-names>V.</given-names></name><name><surname>Shattock</surname><given-names>R.J.</given-names></name><name><surname>Montefiori</surname><given-names>D.C.</given-names></name><name><surname>Bakke</surname><given-names>J.</given-names></name><name><surname>Mirsalis</surname><given-names>J.</given-names></name><name><surname>d&#x02019;Andrea</surname><given-names>A.L.</given-names></name><name><surname>Hume</surname><given-names>S.D.</given-names></name><name><surname>Bratcher</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2009</year><volume>106</volume><fpage>6099</fpage><lpage>6104</lpage><pub-id pub-id-type="doi">10.1073/pnas.0901506106</pub-id><pub-id pub-id-type="pmid">19332801</pub-id></element-citation></ref><ref id="B46-marinedrugs-17-00567"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barton</surname><given-names>C.</given-names></name><name><surname>Kouokam</surname><given-names>J.C.</given-names></name><name><surname>Hurst</surname><given-names>H.</given-names></name><name><surname>Palmer</surname><given-names>K.E.</given-names></name></person-group><article-title>Pharmacokinetics of the antiviral lectin griffithsin administered by different routes indicates multiple potential uses</article-title><source>Viruses</source><year>2016</year><volume>8</volume><elocation-id>331</elocation-id><pub-id pub-id-type="doi">10.3390/v8120331</pub-id></element-citation></ref><ref id="B47-marinedrugs-17-00567"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farr Zuend</surname><given-names>C.</given-names></name><name><surname>Nomellini</surname><given-names>J.F.</given-names></name><name><surname>Smit</surname><given-names>J.</given-names></name><name><surname>Horwitz</surname><given-names>M.S.</given-names></name></person-group><article-title>A caulobacter crescentus microbicide protects from vaginal infection with HIV-1JR-CSF in humanized bone marrow-liver-thymus mice</article-title><source>J. Virol.</source><year>2019</year><volume>3</volume><fpage>e00614-19</fpage><pub-id pub-id-type="doi">10.1128/JVI.00614-19</pub-id></element-citation></ref><ref id="B48-marinedrugs-17-00567"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuqua</surname><given-names>J.L.</given-names></name><name><surname>Wanga</surname><given-names>V.</given-names></name><name><surname>Palmer</surname><given-names>K.E.</given-names></name></person-group><article-title>Improving the large scale purification of the HIV microbicide, griffithsin</article-title><source>BMC Biotechnol.</source><year>2015</year><volume>15</volume><elocation-id>12</elocation-id><pub-id pub-id-type="doi">10.1186/s12896-015-0120-5</pub-id><pub-id pub-id-type="pmid">25887919</pub-id></element-citation></ref><ref id="B49-marinedrugs-17-00567"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giomarelli</surname><given-names>B.</given-names></name><name><surname>Schumacher</surname><given-names>K.M.</given-names></name><name><surname>Taylor</surname><given-names>T.E.</given-names></name><name><surname>Sowder</surname><given-names>R.C.</given-names><suffix>2nd</suffix></name><name><surname>Hartley</surname><given-names>J.L.</given-names></name><name><surname>McMahon</surname><given-names>J.B.</given-names></name><name><surname>Mori</surname><given-names>T.</given-names></name></person-group><article-title>Recombinant production of anti-HIV protein, griffithsin, by auto-induction in a fermentor culture</article-title><source>Protein Expr. Purif.</source><year>2006</year><volume>47</volume><fpage>194</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/j.pep.2005.10.014</pub-id><pub-id pub-id-type="pmid">16300962</pub-id></element-citation></ref><ref id="B50-marinedrugs-17-00567"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>S.</given-names></name><name><surname>Giritch</surname><given-names>A.</given-names></name><name><surname>Bartels</surname><given-names>D.</given-names></name><name><surname>Bortesi</surname><given-names>L.</given-names></name><name><surname>Gleba</surname><given-names>Y.</given-names></name></person-group><article-title>A novel and fully scalable agrobacterium spray-based process for manufacturing cellulases and other cost-sensitive proteins in plants</article-title><source>Plant. Biotechnol. J.</source><year>2015</year><volume>13</volume><fpage>708</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1111/pbi.12299</pub-id><pub-id pub-id-type="pmid">25470212</pub-id></element-citation></ref><ref id="B51-marinedrugs-17-00567"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrova</surname><given-names>M.I.</given-names></name><name><surname>van den Broek</surname><given-names>M.F.L.</given-names></name><name><surname>Spacova</surname><given-names>I.</given-names></name><name><surname>Verhoeven</surname><given-names>T.L.A.</given-names></name><name><surname>Balzarini</surname><given-names>J.</given-names></name><name><surname>Vanderleyden</surname><given-names>J.</given-names></name><name><surname>Schols</surname><given-names>D.</given-names></name><name><surname>Lebeer</surname><given-names>S.</given-names></name></person-group><article-title>Engineering lactobacillus rhamnosus GG and GR-1 to express HIV-inhibiting griffithsin</article-title><source>Int. J. Antimicrob. Agents</source><year>2018</year><volume>52</volume><fpage>599</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2018.07.013</pub-id><?supplied-pmid 30040991?><pub-id pub-id-type="pmid">30040991</pub-id></element-citation></ref><ref id="B52-marinedrugs-17-00567"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vamvaka</surname><given-names>E.</given-names></name><name><surname>Arcalis</surname><given-names>E.</given-names></name><name><surname>Ramessar</surname><given-names>K.</given-names></name><name><surname>Evans</surname><given-names>A.</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>B.R.</given-names></name><name><surname>Shattock</surname><given-names>R.J.</given-names></name><name><surname>Medina</surname><given-names>V.</given-names></name><name><surname>Stoger</surname><given-names>E.</given-names></name><name><surname>Christou</surname><given-names>P.</given-names></name><name><surname>Capell</surname><given-names>T.</given-names></name></person-group><article-title>Rice endosperm is cost-effective for the production of recombinant griffithsin with potent activity against HIV</article-title><source>Plant. Biotechnol. J.</source><year>2016</year><volume>14</volume><fpage>1427</fpage><lpage>1437</lpage><pub-id pub-id-type="doi">10.1111/pbi.12507</pub-id><?supplied-pmid 26800650?><pub-id pub-id-type="pmid">26800650</pub-id></element-citation></ref><ref id="B53-marinedrugs-17-00567"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoelscher</surname><given-names>M.</given-names></name><name><surname>Tiller</surname><given-names>N.</given-names></name><name><surname>Teh</surname><given-names>A.Y.</given-names></name><name><surname>Wu</surname><given-names>G.Z.</given-names></name><name><surname>Ma</surname><given-names>J.K.</given-names></name><name><surname>Bock</surname><given-names>R.</given-names></name></person-group><article-title>High-level expression of the HIV entry inhibitor griffithsin from the plastid genome and retention of biological activity in dried tobacco leaves</article-title><source>Plant. Mol. Biol.</source><year>2018</year><volume>97</volume><fpage>357</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1007/s11103-018-0744-7</pub-id><?supplied-pmid 29948657?><pub-id pub-id-type="pmid">29948657</pub-id></element-citation></ref><ref id="B54-marinedrugs-17-00567"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>B.M.</given-names></name><name><surname>Lotter-Stark</surname><given-names>H.C.T.</given-names></name><name><surname>Rybicki</surname><given-names>E.P.</given-names></name><name><surname>Chikwamba</surname><given-names>R.K.</given-names></name><name><surname>Palmer</surname><given-names>K.E.</given-names></name></person-group><article-title>Characterization of the hypersensitive response-like cell death phenomenon induced by targeting antiviral lectin griffithsin to the secretory pathway</article-title><source>Plant. Biotechnol. J.</source><year>2018</year><volume>16</volume><fpage>1811</fpage><lpage>1821</lpage><pub-id pub-id-type="doi">10.1111/pbi.12917</pub-id><?supplied-pmid 29509998?><pub-id pub-id-type="pmid">29509998</pub-id></element-citation></ref><ref id="B55-marinedrugs-17-00567"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vamvaka</surname><given-names>E.</given-names></name><name><surname>Farre</surname><given-names>G.</given-names></name><name><surname>Molinos-Albert</surname><given-names>L.M.</given-names></name><name><surname>Evans</surname><given-names>A.</given-names></name><name><surname>Canela-Xandri</surname><given-names>A.</given-names></name><name><surname>Twyman</surname><given-names>R.M.</given-names></name><name><surname>Carrillo</surname><given-names>J.</given-names></name><name><surname>Ordonez</surname><given-names>R.A.</given-names></name><name><surname>Shattock</surname><given-names>R.J.</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>B.R.</given-names></name><etal/></person-group><article-title>Unexpected synergistic HIV neutralization by a triple microbicide produced in rice endosperm</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2018</year><volume>115</volume><fpage>E7854</fpage><lpage>E7862</lpage><pub-id pub-id-type="doi">10.1073/pnas.1806022115</pub-id><?supplied-pmid 30061386?><pub-id pub-id-type="pmid">30061386</pub-id></element-citation></ref><ref id="B56-marinedrugs-17-00567"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moncla</surname><given-names>B.J.</given-names></name><name><surname>Pryke</surname><given-names>K.</given-names></name><name><surname>Rohan</surname><given-names>L.C.</given-names></name><name><surname>Graebing</surname><given-names>P.W.</given-names></name></person-group><article-title>Degradation of naturally occurring and engineered antimicrobial peptides by proteases</article-title><source>Adv. Biosci. Biotechnol.</source><year>2011</year><volume>2</volume><fpage>404</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.4236/abb.2011.26059</pub-id><pub-id pub-id-type="pmid">22611520</pub-id></element-citation></ref><ref id="B57-marinedrugs-17-00567"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grooms</surname><given-names>T.N.</given-names></name><name><surname>Vuong</surname><given-names>H.R.</given-names></name><name><surname>Tyo</surname><given-names>K.M.</given-names></name><name><surname>Malik</surname><given-names>D.A.</given-names></name><name><surname>Sims</surname><given-names>L.B.</given-names></name><name><surname>Whittington</surname><given-names>C.P.</given-names></name><name><surname>Palmer</surname><given-names>K.E.</given-names></name><name><surname>Matoba</surname><given-names>N.</given-names></name><name><surname>Steinbach-Rankins</surname><given-names>J.M.</given-names></name></person-group><article-title>Griffithsin-modified electrospun fibers as a delivery scaffold to prevent HIV infection</article-title><source>Antimicrob. Agents Chemother.</source><year>2016</year><volume>60</volume><fpage>6518</fpage><lpage>6531</lpage><pub-id pub-id-type="doi">10.1128/AAC.00956-16</pub-id><pub-id pub-id-type="pmid">27550363</pub-id></element-citation></ref><ref id="B58-marinedrugs-17-00567"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lal</surname><given-names>M.</given-names></name><name><surname>Lai</surname><given-names>M.</given-names></name><name><surname>Ugaonkar</surname><given-names>S.</given-names></name><name><surname>Wesenberg</surname><given-names>A.</given-names></name><name><surname>Kizima</surname><given-names>L.</given-names></name><name><surname>Rodriguez</surname><given-names>A.</given-names></name><name><surname>Levendosky</surname><given-names>K.</given-names></name><name><surname>Mizenina</surname><given-names>O.</given-names></name><name><surname>Fernandez-Romero</surname><given-names>J.</given-names></name><name><surname>Zydowsky</surname><given-names>T.</given-names></name></person-group><article-title>Development of a vaginal fast-dissolving insert combining griffithsin and carrageenan for potential use against sexually transmitted infections</article-title><source>J. Pharm. Sci.</source><year>2018</year><volume>107</volume><fpage>2601</fpage><lpage>2610</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2018.06.002</pub-id><pub-id pub-id-type="pmid">29902477</pub-id></element-citation></ref><ref id="B59-marinedrugs-17-00567"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyo</surname><given-names>K.M.</given-names></name><name><surname>Duan</surname><given-names>J.</given-names></name><name><surname>Kollipara</surname><given-names>P.</given-names></name><name><surname>Dela Cerna</surname><given-names>M.V.C.</given-names></name><name><surname>Lee</surname><given-names>D.</given-names></name><name><surname>Palmer</surname><given-names>K.E.</given-names></name><name><surname>Steinbach-Rankins</surname><given-names>J.M.</given-names></name></person-group><article-title>pH-responsive delivery of griffithsin from electrospun fibers</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2019</year><volume>138</volume><fpage>64</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2018.04.013</pub-id><pub-id pub-id-type="pmid">29698714</pub-id></element-citation></ref><ref id="B60-marinedrugs-17-00567"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Patel</surname><given-names>S.K.</given-names></name><name><surname>Palmer</surname><given-names>K.E.</given-names></name><name><surname>Devlin</surname><given-names>B.</given-names></name><name><surname>Rohan</surname><given-names>L.C.</given-names></name></person-group><article-title>Design of poly(lactic-co-glycolic acid) (PLGA) nanoparticles for vaginal co-delivery of griffithsin and dapivirine and their synergistic effect for HIV prophylaxis</article-title><source>Pharmaceutics</source><year>2019</year><volume>11</volume><elocation-id>184</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics11040184</pub-id></element-citation></ref><ref id="B61-marinedrugs-17-00567"><label>61.</label><element-citation publication-type="gov"><article-title>Study to Evaluate the Safety of Griffithsin in a Carrageenan Gel in Healthy Women</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT02875119">https://clinicaltrials.gov/ct2/show/study/NCT02875119</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-10-05">(accessed on 5 October 2019)</date-in-citation></element-citation></ref><ref id="B62-marinedrugs-17-00567"><label>62.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>K.E.</given-names></name></person-group><article-title>Griffithsin-based Rectal Microbicides for Prevention of Viral Entry (PREVENT)</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04032717?term=griffithsin&#x00026;rank=2">https://clinicaltrials.gov/ct2/show/NCT04032717?term=griffithsin&#x00026;rank=2</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-10-05">(accessed on 5 October 2019)</date-in-citation></element-citation></ref><ref id="B63-marinedrugs-17-00567"><label>63.</label><element-citation publication-type="web"><article-title>Developing and Testing a Griffithsin (non-ARV) Microbicide</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.popcouncil.org/research/developing-and-testing-a-griffithsin-non-arv-microbicide">https://www.popcouncil.org/research/developing-and-testing-a-griffithsin-non-arv-microbicide</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-10-05">(accessed on 5 October 2019)</date-in-citation></element-citation></ref><ref id="B64-marinedrugs-17-00567"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farr Zuend</surname><given-names>C.</given-names></name><name><surname>Nomellini</surname><given-names>J.F.</given-names></name><name><surname>Smit</surname><given-names>J.</given-names></name><name><surname>Horwitz</surname><given-names>M.S.</given-names></name></person-group><article-title>Generation of a dual-target, safe, inexpensive microbicide that protects against HIV-1 and HSV-2 disease</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>2786</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-21134-1</pub-id><?supplied-pmid 29434285?><pub-id pub-id-type="pmid">29434285</pub-id></element-citation></ref><ref id="B65-marinedrugs-17-00567"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Izquierdo</surname><given-names>L.</given-names></name><name><surname>Oliveira</surname><given-names>C.</given-names></name><name><surname>Fournier</surname><given-names>C.</given-names></name><name><surname>Descamps</surname><given-names>V.</given-names></name><name><surname>Morel</surname><given-names>V.</given-names></name><name><surname>Dubuisson</surname><given-names>J.</given-names></name><name><surname>Brochot</surname><given-names>E.</given-names></name><name><surname>Francois</surname><given-names>C.</given-names></name><name><surname>Castelain</surname><given-names>S.</given-names></name><name><surname>Duverlie</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Hepatitis C virus resistance to carbohydrate-binding agents</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0149064</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0149064</pub-id><?supplied-pmid 26871442?><pub-id pub-id-type="pmid">26871442</pub-id></element-citation></ref><ref id="B66-marinedrugs-17-00567"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derby</surname><given-names>N.</given-names></name><name><surname>Lal</surname><given-names>M.</given-names></name><name><surname>Aravantinou</surname><given-names>M.</given-names></name><name><surname>Kizima</surname><given-names>L.</given-names></name><name><surname>Barnable</surname><given-names>P.</given-names></name><name><surname>Rodriguez</surname><given-names>A.</given-names></name><name><surname>Lai</surname><given-names>M.</given-names></name><name><surname>Wesenberg</surname><given-names>A.</given-names></name><name><surname>Ugaonkar</surname><given-names>S.</given-names></name><name><surname>Levendosky</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Griffithsin carrageenan fast dissolving inserts prevent SHIV HSV-2 and HPV infections in vivo</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>3881</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-06349-0</pub-id><?supplied-pmid 30250170?><pub-id pub-id-type="pmid">30250170</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="marinedrugs-17-00567-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>The amino acid sequence of griffithsin (GRFT). Corresponding secondary &#x003b2;-sheet structures are marked with yellow arrows based on the crystal structure of a GRFT dimer with mannose at a resolution of 1.78 &#x000c5; [<xref rid="B19-marinedrugs-17-00567" ref-type="bibr">19</xref>]. Tyrosine and aspartate residues in three carbohydrate-binding domains, which are essential for mannose-binding, are noted with blue and orange arrows, respectively. Wild-type GRFT has a non-standard amino acid at position 31, but it is replaced by alanine (colored in red) in recombinant GRFT. The sequence display was generated by the RCSB protein data bank website (<uri xlink:href="www.rcsb.org">www.rcsb.org</uri>).</p></caption><graphic xlink:href="marinedrugs-17-00567-g001"/></fig><fig id="marinedrugs-17-00567-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>The crystal structure of a GRFT dimer with six mannoses at a resolution of 1.78 &#x000c5; [<xref rid="B19-marinedrugs-17-00567" ref-type="bibr">19</xref>]. Each GRFT monomer is presented in either red or blue. Six bound mannose molecules are shown with ball and stick models. This image was created with PDB ID and associated publication, NGL Viewer (AS Rose et al. (2018) NGL viewer: web-based molecular graphics for large complexes. Bioinformatics doi:10.1093/bioinformatics/bty419), and RCSB PDB.</p></caption><graphic xlink:href="marinedrugs-17-00567-g002"/></fig><table-wrap id="marinedrugs-17-00567-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">marinedrugs-17-00567-t001_Table 1</object-id><label>Table 1</label><caption><p>Five structural studies involving GRFT. The structure resolution of GRFT and its major characteristics are presented.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Structure Studied</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Crystal Resolution (A&#x000b0;)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Structural and Functional Characteristics</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GRFT alone or with mannose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3 and 0.94</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A domain-swapped dimer, a Jacalin-related lectin with a &#x003b2;-prism motif, and three identical mannose-binding sites on each monomer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B19-marinedrugs-17-00567" ref-type="bibr">19</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GRFT with glucose or <italic>N</italic>-acetylglucosamine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30&#x02013;1.50 and 30&#x02013;1.56</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All six monosaccharide binding sites of GRFT are occupied by both glucose and <italic>N</italic>-acetylglucosamine with a mode of binding similar to that of mannose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B23-marinedrugs-17-00567" ref-type="bibr">23</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GRFT with 1-6&#x003b1;-mannobiose or maltose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.0 and 1.5</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The binding of 1-6&#x003b1;-mannobiose is similar to that of mannose and the binding of maltose is weaker than that of mannose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B22-marinedrugs-17-00567" ref-type="bibr">22</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monomeric GRFT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30&#x02013;0.97</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduced activity against HIV-1 due to a loss of multivalent interaction and the binding of a monomeric GRFT to two different nona-mannosides</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B20-marinedrugs-17-00567" ref-type="bibr">20</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GRFT with a disrupted carbohydrate-binding site</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NMR study</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduced binding to mannose and a weaker correlation between anti-HIV-1 activity and gp120 binding</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B21-marinedrugs-17-00567" ref-type="bibr">21</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="marinedrugs-17-00567-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">marinedrugs-17-00567-t002_Table 2</object-id><label>Table 2</label><caption><p>Anti-HIV-1 activity and cytotoxicity of GRFT in vitro. N/A indicates &#x0201c;not applicable.&#x0201d;</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HIV-1 Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cell Line</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Anti-HIV-1 Assay Readout</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">EC<sub>50</sub> (nM)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CC<sub>50</sub> (nM)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Laboratory strains and primary isolates of T- and M-tropic HIV-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CEM-SS cells, PBMC, and macrophage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virus-induced cell killing</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.043&#x02013;0.63</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;783</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B5-marinedrugs-17-00567" ref-type="bibr">5</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CXCR4-and CCR5-tropic HIV-1, SHIV strains, and SIVmac251</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CEM-174, MT-2, MT-4, and PBMC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">p24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;500</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-marinedrugs-17-00567" ref-type="bibr">27</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV-1 subtype C primary virus isolates</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TZM-bl and PBMC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TZM-bl and p24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B25-marinedrugs-17-00567" ref-type="bibr">25</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV-1 CCR5-tropic strain ADA and CXCR4-tropic strain HXB2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HeLa-ADA effector cells and HeLa-P5L CCR5-bearing target cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CCR5-tropic cell-cell fusion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-marinedrugs-17-00567" ref-type="bibr">32</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV-1 clade B and clade C isolates</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PBMCs and CD4+ MT-4 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">p24 HIV-1 core Ag ELISA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-marinedrugs-17-00567" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV-1 subtype B QH0515 and C SW7 and Du179</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Raji/DC-SIGN cells and TZM-bl cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV-1 binding to the DC-SIGN receptor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">345</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B26-marinedrugs-17-00567" ref-type="bibr">26</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV-1 subtype B QH0515 and C SW7 and Du179</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Raji/DC-SIGN cells and TZM-bl cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV-1 bound Raji cells transferred to CD4 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.8&#x02013;35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B26-marinedrugs-17-00567" ref-type="bibr">26</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV-1 X4 strain IIIB and dual-tropic R5/X4 HIV-1 strain HE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Persistently HIV-infected T cells and noninfected CD4+ target T cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Giant cell formation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.087</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-marinedrugs-17-00567" ref-type="bibr">28</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV-1 X4 strain IIIB and dual-tropic R5/X4 HIV-1 strain HE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Raji.DC-SIGN cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DC-SIGN mediated HIV transmission</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.025</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-marinedrugs-17-00567" ref-type="bibr">28</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV-1(IIIB) and HIV NL4.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CEM, C8166, HuT-78, and Sup-T1 cells, Raji/DC-SIGN cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DC-SIGN-mediated virus capture</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-marinedrugs-17-00567" ref-type="bibr">30</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV-1(IIIB) and HIV NL4.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CEM, C8166, HuT-78, and Sup-T1 cells, Raji/DC-SIGN cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV-1 transmission to CD4+ T-lymphocytes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.012</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-marinedrugs-17-00567" ref-type="bibr">30</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single transmitted/founder HIV-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TZM-bl cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neutralization assay using pseudotyped viruses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.006&#x02013;10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B31-marinedrugs-17-00567" ref-type="bibr">31</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="marinedrugs-17-00567-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">marinedrugs-17-00567-t003_Table 3</object-id><label>Table 3</label><caption><p>Drug combination results with GRFT.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cell Line</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Assay Readout</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Combination Drug</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Result</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PBMCs and CD4+ MT-4 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">p24 HIV-1 core Ag ELISA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tenofovir, maraviroc, and enfuvirtide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synergy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-marinedrugs-17-00567" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HeLa-ADA effector cells and HeLa-P5L CCR5-bearing target cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CCR5-tropic cell-cell fusion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Covalently linked gp41-binding peptide C37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synergy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-marinedrugs-17-00567" ref-type="bibr">32</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TZM-bl cells, U87-CCR5 and U87-CXCR4.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pseudovirus neutralization</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2G12 mAb</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synergy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B26-marinedrugs-17-00567" ref-type="bibr">26</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Persistently HIV-infected T cells and noninfected CD4+ target T cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Giant cell formation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Efavirenz, tenofovir, raltegravir, and elvitegravir</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synergy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-marinedrugs-17-00567" ref-type="bibr">28</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Raji.DC-SIGN cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DC-SIGN mediated HIV transmission</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tenofovir, saquinavir, and 2G12 mAb</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synergy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-marinedrugs-17-00567" ref-type="bibr">28</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MT-4 cells, PBMC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virus-induced cytopathic effect</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Microvirin, 2G12 mAb, BanLec, and HHA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synergy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-marinedrugs-17-00567" ref-type="bibr">28</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="marinedrugs-17-00567-t004" orientation="portrait" position="float"><object-id pub-id-type="pii">marinedrugs-17-00567-t004_Table 4</object-id><label>Table 4</label><caption><p>GRFT anti-HIV-1 mechanisms of action.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">The Effect of GRFT on HIV-1 gp120</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Exposure of the CD4 binding site of gp120 through the glycan at position 386 and blockage of coreceptor binding step</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B26-marinedrugs-17-00567" ref-type="bibr">26</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of mannose-binding to gp120 and improvement of the humoral immune response to gp120</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B34-marinedrugs-17-00567" ref-type="bibr">34</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of gp120 binding to DC-SIGN and expulsion of gp120 from the gp120/DC-SIGN complex</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-marinedrugs-17-00567" ref-type="bibr">30</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alteration of gp120 structure through the exposure of the CD4 binding site</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-marinedrugs-17-00567" ref-type="bibr">37</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intra-virion crosslinking of gp120</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B36-marinedrugs-17-00567" ref-type="bibr">36</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inter-virion aggregation or clustering of gp120</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B35-marinedrugs-17-00567" ref-type="bibr">35</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="marinedrugs-17-00567-t005" orientation="portrait" position="float"><object-id pub-id-type="pii">marinedrugs-17-00567-t005_Table 5</object-id><label>Table 5</label><caption><p>HIV-1 resistance mechanisms against GRFT.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HIV Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cell Line</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Assay Readout</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Resistance Mechanism</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV-1 subtype C primary virus isolates</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TZM-bl and PBMC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV-1 neutralization assay</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Loss of glycans at positions 234 and 295</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B25-marinedrugs-17-00567" ref-type="bibr">25</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary and T-cell-line-adapted HIV-1 isolates</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TZM-bl cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Env-pseudotyped viruses to infect TZM-bl cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Loss of glycan at position 295 and 448</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B40-marinedrugs-17-00567" ref-type="bibr">40</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV-1 subtype C primary virus isolates</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Raji/DC-SIGN cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The DC-SIGN-mediated HIV-1 transfer to TZM-bl cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Introduction of a glycan at position 234</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-marinedrugs-17-00567" ref-type="bibr">38</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV-1 subtype C primary virus isolates</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TheTZM-bl and PBMC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV-1 neutralization assay in PBMC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Loss of glycan at positions 230, 234, 339, 392, and 448</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B39-marinedrugs-17-00567" ref-type="bibr">39</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single transmitted/founder HIV-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TZM-bl cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neutralization assay using pseudotyped viruses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Loss of glycan at positions 295, 339, and 448</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B31-marinedrugs-17-00567" ref-type="bibr">31</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="marinedrugs-17-00567-t006" orientation="portrait" position="float"><object-id pub-id-type="pii">marinedrugs-17-00567-t006_Table 6</object-id><label>Table 6</label><caption><p>Toxicity studies of GRFT in various cell and animal models.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Models Used</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dose Tested</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Effects of GRFT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human cervical explants and rabbits</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Up to 2 &#x003bc;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No effect on the production of proinflammatory cytokines and chemokines.<break/>No vaginal irritation in rabbits.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B45-marinedrugs-17-00567" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human cervical epithelial cells, cervicovaginal cells, and PBMCs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Up to 84 &#x003bc;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Minimal changes in secretion of inflammatory cytokines and chemokines<break/>No measurable effect on cell viability and T-cell activation markers.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B43-marinedrugs-17-00567" ref-type="bibr">43</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Guinea pig<break/>BALB/c mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single 50 mg/kg and 10 daily subcutaneous injections of 10 mg/kg </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Minimal overall toxicity.<break/>Well tolerated.<break/>Increase in spleen and liver mass.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B41-marinedrugs-17-00567" ref-type="bibr">41</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mouse PBMC and BALB/c mice with parenteral administration</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Up to 4 &#x003bc;M in vitro, subcutaneously with a single dose of 10 mg/kg, fourteen daily doses of 10 mg/kg, 2 mg/kg subcutaneous, intravaginal, and intraperitoneal administration</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No mitogenic properties in vitro.<break/>No effect on cell surface activation markers or animal fitness.<break/>No major organ toxicity with reversible splenomegaly.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B44-marinedrugs-17-00567" ref-type="bibr">44</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rhesus macaques</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravaginal 0.1% gels</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No change in rental proteome or microbiome</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B42-marinedrugs-17-00567" ref-type="bibr">42</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="marinedrugs-17-00567-t007" orientation="portrait" position="float"><object-id pub-id-type="pii">marinedrugs-17-00567-t007_Table 7</object-id><label>Table 7</label><caption><p>In vivo anti-HIV-1 activity of GRFT in animal models.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Models Used</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dose Tested</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Effects of GRFT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Guinea pig<break/>BALB/c mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single 50 mg/kg and 10 daily subcutaneous injections of 10 mg/kg.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retention of antiviral activity in serum</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B41-marinedrugs-17-00567" ref-type="bibr">41</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sprague Dawley (SD) rats</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A single dose of 10 mg/mL intravenously or subcutaneously.<break/>Ten 40 mg/kg doses for 10 days.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neutralization activity found in fecal extracts</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B46-marinedrugs-17-00567" ref-type="bibr">46</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Humanized bone marrow-liver-thymus mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>8</sup> GRFT-expressing recombinant <italic>C. crescentus</italic> intravaginally.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protection against HIV-1 infection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B47-marinedrugs-17-00567" ref-type="bibr">47</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="marinedrugs-17-00567-t008" orientation="portrait" position="float"><object-id pub-id-type="pii">marinedrugs-17-00567-t008_Table 8</object-id><label>Table 8</label><caption><p>Large-scale GRFT production methods. N/A indicates &#x0201c;not applicable.&#x0201d;</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Production Method</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Expression Organism</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Effects and Yield</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Transformation and the use of an autoinduction fermentor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Escherichia coli</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45-fold increase</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B49-marinedrugs-17-00567" ref-type="bibr">49</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Transduction with tobacco mosaic virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Nicotiana benthamiana</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multigram quantity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B45-marinedrugs-17-00567" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Agrobacterium vectors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Nicotiana benthamiana</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90% of the leaf cells and 50% of the total soluble protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B50-marinedrugs-17-00567" ref-type="bibr">50</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Transduction with tobacco mosaic virus in pH 4 buffer, heating the extract to 55 &#x000b0;C, a bentonite MgCl<sub>2</sub> mixture, and chromatography.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Nicotiana benthamiana</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88% &#x000b1; 5% of griffithsin from the initial extract</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B48-marinedrugs-17-00567" ref-type="bibr">48</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Particle bombardment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rice endosperm</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">223 &#x003bc;g/g dry seed weight</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B52-marinedrugs-17-00567" ref-type="bibr">52</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Use of probiotic microorganisms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>Lactobacillus rhamnosus GG</italic> and <italic>L. rhamnosus GR-1</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B51-marinedrugs-17-00567" ref-type="bibr">51</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chloroplast transformation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Nicotiana tabacum</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">360 &#x003bc;g of pure griffithsin per gram</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B53-marinedrugs-17-00567" ref-type="bibr">53</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="marinedrugs-17-00567-t009" orientation="portrait" position="float"><object-id pub-id-type="pii">marinedrugs-17-00567-t009_Table 9</object-id><label>Table 9</label><caption><p>Pharmaceutical formulations for the efficient delivery of GRFT.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Formulation Method</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Delivery Route</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Effects on Delivery</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLGA nanoparticles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaginal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A biphasic release with an initial burst phase followed by a sustained release phase</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B60-marinedrugs-17-00567" ref-type="bibr">60</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Electrospun fibers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Maintenance of antiviral efficacy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B57-marinedrugs-17-00567" ref-type="bibr">57</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDI comprised of</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaginal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Good friability, hardness, and stability</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B58-marinedrugs-17-00567" ref-type="bibr">58</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mPEG-PLGA:PBA-co-PAA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaginal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High GRFT loading and pH-dependent release</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B59-marinedrugs-17-00567" ref-type="bibr">59</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>